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ABSTRACT 
 
Children with clustering of cardiometabolic risk factors have an increased risk of adulthood 
metabolic syndrome (MetS), type 2 diabetes and cardiovascular disease. MetS has also been 
associated with liver fat accumulation already in children. Elevated levels of plasma alanine 
aminotransferase (ALT) and gamma-glutamyltransferase (GGT) have been associated with 
liver fat accumulation. In addition to excess body fat, also genetic factors, and mainly 
PNPLA3 I148M polymorphism, have been found to increase the risk of liver fat 
accumulation not only in adults but also in children.  
   The purpose of this thesis was to expand knowledge on the clustering of cardiometabolic 
risk factors in children and adults, the associations of cardiometabolic risk factors with 
plasma levels of ALT and GGT in children and the relationship of the I148M polymorphism 
in the PNPLA3 gene with plasma ALT and GGT levels in children. Data on children were 
from the Physical Activity and Nutrition in Children (PANIC) Study, which is an ongoing 
exercise and diet intervention study in a population sample of children from the city of 
Kuopio, Finland. Altogether 512 children 6-8 years of age participated in the baseline study 
and 440 of them also took part in the 2-year follow-up study. Data on adults were from a 
large follow-up study in middle-aged men and from baseline examinations of a large 
randomized controlled trial among older individuals. 
  Factor analysis was used to derive the MetS. MetS was represented by a second-order 
latent variable underlying four latent variables characterized by abdominal obesity, insulin 
resistance, dyslipidemia and raised blood pressure in different age groups. These second-
order factors were strongly associated with a composite cardiometabolic risk score in all 
age groups (r=0.84-0.99) and similarly predicted type 2 diabetes, cardiovascular outcomes 
and mortality in middle-aged men. The risk of type 2 diabetes, myocardial infarction and 
cardiovascular death increased 3.7-, 1.4-, and 1.6-fold, respectively, for a 1 SD increase in 
the cardiometabolic risk score. Overweight or obese children had a 2.1-times higher risk of 
having ALT and a 4.5-times higher risk of having GGT in the highest fifth than normal-
weight children. Overweight PNPLA3 148M allele carriers had higher ALT levels (23.2 U/l) 
at baseline than other children (18.2-19.2 U/l) (P=0.024 for interaction). Moreover, they had a 
larger increase (6.4 U/l) in ALT levels during 2-year follow-up than other children (-0.6−0.3 
U/l) (P=0.002 for interaction)  
   The findings show that MetS can be described as a single entity in widely varying age 
groups and that the cardiometabolic risk score is a valid tool for research evaluating 
cardiometabolic risk in different age groups. Moreover, cardiometabolic risk score and 
individual risk factors were associated with high-normal plasma levels of ALT and 
particularly GGT in children. Furthermore, the carriers of 148M allele of the PNPLA3 
rs738409 polymorphism had elevated plasma levels of ALT if they were overweight but not 
if they were normal weight. 
National Library of Medicine Classification: QU 141, QU 500, WD 200, WD 210, WK 820  
Medical Subject Headings: Metabolic Syndrome X; Risk Factors; Overweight; Obesity, Abdominal; Insulin 
Resistance; Dyslipidemias; Blood Pressure; Diabetes Mellitus, Type 2;  Myocardial Infarction; Alanine 
Transaminase; gamma-Glutamyltransferase; Genes; Polymorphism, Genetic; Child; Middle Aged; Finland 
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TIIVISTELMÄ 
 
Lapsuusiässä ilmaantuneet kardiometaboliset riskitekijät säilyvät usein aikuisikään saakka 
lisäten metabolisen oireyhtymän, tyypin 2 diabeteksen ja ateroskleroottisten valtimotautien 
riskiä aikuisiässä. Kardiometabolisten riskitekijöiden kasaumaan voi liittyä myös 
lisääntynyt maksan rasvoittuminen, jonka yhteydessä plasman alaniiniaminotransferaasi 
(ALAT) ja gamma-glutamyylitransferaasi (GT) arvot nousevat. Geneettisistä tekijöitä 
erityisesti PNPLA3 I148M genotyyppi on ollut yhteydessä maksan rasvoittumiseen sekä 
aikuisilla että lapsilla. Tämän tutkimuksen tarkoituksena oli lisätä tietoa metabolisten 
riskitekijöiden kasautumisesta lapsilla ja aikuisilla ja sen yhteydestä ALAT- ja GT-arvojen 
tasoihin lapsilla. Lisäksi tavoitteena oli tutkia PNPLA3 I148M polymorfismin yhteyttä 
ALAT- ja GT-tasoihin lapsilla. Väitöskirja perustuu kolmeen kuopiolaiseen väestöotokseen. 
Lasten liikunta ja ravitsemus -tutkimus on käynnissä oleva interventiotutkimus 512 6-8-
vuotiaan lapsen edustavassa väestöotoksessa, jonka 2-vuoden seurantatutkimukseen 
osallistui 440 lasta. Aikuisväestön aineisto oli peräisin suuresta keski-ikäisillä miehillä 
toteutetusta seurantatutkimuksesta sekä ikääntyvillä naisilla ja miehillä toteutetusta 
laajasta kohorttitutkimuksesta. 
  Toisen asteen faktorianalyysimalli muodostettiin neljästä muuttujasta, jotka kuvasivat 
lisääntynyttä kehon rasvamäärää, insuliiniresistenssiä ja heikentynyttä glukoosinsietoa, 
dyslipidemiaa ja kohonnutta verenpainetta eri ikäryhmissä. Nämä toisen asteen faktorit 
korreloivat vahvasti metabolisen summamuuttujan kanssa kaikissa ikäryhmissä (r=0.84-
0.99) ja ennustivat sen kanssa samankaltaisesti tyypin 2 diabetestä. Summamuuttujan arvon 
noustessa yhden keskihajonnan verran tyypin 2 diabeteksen riski nousi 3.7-kertaiseksi, 
sydäninfarktin riski 1.4-kertaiseksi ja verenkiertoelinsairauksista johtuvien ennenaikaisten 
kuolemien riski 1.6-kertaiseksi. Ylipainoisilla ja lihavilla lapsilla oli 2.1-kertainen riski 
siihen, että ALAT-arvot olivat ylimmässä viidenneksessä ja vastaavasti 4.5-kertainen riski 
GT-arvojen osalta. ALAT-arvot olivat korkeampia ylipainoisilla PNPLA3 -geenin 148M 
alleelia kantavilla lapsilla (23.2 U/l) kuin muilla lapsilla (18.2-19.2 U/l)  lähtötilanteessa 
(interaktion p=0.024). Lisäksi 2-vuoden aikana ALAT-arvoissa tapahtui heillä (6.4 U/l) 
muita (-0.6−0.3 U/l) suurempi ALAT-arvojen nousu (interaktion p=0.002). 
   Tulokset osoittivat metabolisen oireyhtymän osatekijöiden kasautuvan samankaltaisesti 
lapsilla ja eri-ikäisillä aikuisilla sukupuolesta riippumatta. Aineenvaihdunnallista riskiä 
kuvaava summamuuttuja osoittautui käyttökelpoiseksi arviointivälineeksi eri ikäluokissa. 
Metabolisten riskitekijöiden kasautuminen oli yhteydessä lievästi kohonneisiin ALAT- ja 
erityisesti GT-pitoisuuksiin lapsilla ja PNPLA3 I148M alleelin kantajuuden ja ylipainon 
yhteisvaikutus oli yhteydessä korkeampiin ALAT-arvoihin lapsilla. 
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1 Introduction 
The metabolic syndrome (MetS) is a cluster of cardiometabolic risk factors, including 
central obesity, insulin resistance, glucose intolerance, dyslipidemia and raised blood 
pressure (1,2). The prevalence of MetS is increasing worldwide due to the epidemic of 
overweight and obesity (3,4). Children with MetS have an increased risk of adulthood 
MetS, type 2 diabetes and cardiovascular disease (CVD) (5,6). MetS also predicts type 2 
diabetes (7), CVD (8,9), CVD and all-cause mortality (10) in adults. Thus, there is an urgent 
need to better understand the pathophysiology and determinants of this risk factor 
clustering already in childhood. It is also important to understand whether the structure of 
MetS is similar in different stages of life. 
   The definition of MetS is particularly controversial among children and adolescents, 
because there are no clear thresholds above which the cardiometabolic risk factors start to 
worsen (2,11,12). Therefore, many of the more recent studies among children have used 
continuous variables for the components of MetS and have calculated a continuous 
cardiometabolic risk score instead of using a definition based on dichotomous variables (13-
15). Factor analysis has also been used to describe the pathophysiological processes related 
to MetS (16,17). Despite abundant research on MetS using a continuous cardiometabolic 
risk score or factor analysis, there are no previous studies in which the cardiometabolic risk 
score would have been validated by confirmatory factor analysis (CFA) in different age 
groups. Furthermore, few studies have investigated the long-term health consequences of a 
high cardiometabolic risk score (18). 
   In addition to traditional cardiometabolic risk factors, several other metabolic disorders, 
such as liver fat accumulation (19), have been associated with MetS already in children. The 
epidemic of pediatric overweight and obesity has markedly increased the number of 
children with non-alcoholic fatty liver disease (NAFLD) (19,20). Plasma concentrations of 
liver enzymes, such as alanine aminotransferase (ALT) and gamma-glutamyl transferase 
(GGT) may be useful tools in the screening of pediatric NAFLD (21). Little is known about 
the associations of MetS and its components with high-normal plasma ALT and GGT 
concentrations and the role of these liver enzymes as features of MetS in children.  
   Not only excess body fat content but also genetic factors have been found to increase the 
risk of developing NAFLD in children (22,23). Recently the patatin-like phospholipase 
domain-containing protein 3 (PNPLA3) gene variant I148M (rs738409) was found to be 
strongly associated with hepatic steatosis in a genome-wide association study in obese 
adults (24). Thereafter, other studies have provided further evidence that the PNPLA3 gene 
I148M polymorphism is strongly associated with liver fat content and plasma ALT levels in 
obese adults and children (25-27). There is only one previous study on the associations of 
the PNPLA3 148M allele with plasma ALT levels in normal weight and overweight children 
(28) and no follow-up studies on the subject. 
   The purpose of the present study was to investigate the associations of cardiometabolic 
risk factors as well as the I148M polymorphism of the PNPLA3 gene with plasma levels of 
liver enzymes ALT and GGT in prepubertal children. The aim of the present study was also 
to validate the cardiometabolic risk score in different age groups. 
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2 Review of the literature 
2.1 Metabolic syndrome 
2.1.1 Definition of the metabolic syndrome  
Although it has been known for several decades that cardiometabolic risk factors cluster in 
certain individuals, it was not until 1980’s that the real interest for the clustering of 
cardiometabolic abnormalities started. The central roles of insulin resistance and abdominal 
obesity in the pathophysiology of this syndrome became apparent in late 1980’s and early 
1990’s (29,30). Gerald Reaven popularized the syndrome in 1988 by proposing that this 
cluster of abnormalities associated with insulin resistance identifies individuals at increased 
risk for type 2 diabetes and cardiovascular disease (31). Reaven described this phenomenon 
as “Syndrome X” and thereafter several different terms including the Reaven’s syndrome, 
the deadly quartet, the insulin resistance syndrome, the cardiometabolic syndrome, the 
central obesity syndrome, the atherothrombotic syndrome and of course the metabolic 
syndrome have been used in medical literature. More recently, several new components 
including low-grade inflammation, prothrombotic states, liver fat accumulation, 
endothelial dysfunction, hyperuricemia, hypercortisolemia and oxidative stress have been 
linked to MetS, but the core factors still remain the same: central obesity, insulin resistance, 
hyperglycemia, dyslipidemia and raised blood pressure (1,2,12).  
   There appears to be a consensus in the medical field that multiple cardiometabolic risk 
factors for type 2 diabetes and CVD cluster in certain individuals and the term metabolic 
syndrome has been generally accepted to describe this condition. There is still controversy, 
however, about the clinical definition of MetS, and even about the clinical utility of such a 
definition. Over the past decade, various diagnostic criteria have been proposed by 
different expert groups (1,32-36). All these groups agree on the core components of the 
MetS, including obesity, insulin resistance, dyslipidemia and elevated blood pressure, but 
they provide different clinical criteria for identifying such a cluster, which has brought 
some confusion to clinicians (1). Even Gerald Raven himself criticizes these definitions, 
mainly because of including obesity and type 2 diabetes as parts of the definitions, which 
were not included in the definitions of Syndrome X (37). 
   The first attempt to develop a unifying definition for MetS was made by The World 
Health Organization (WHO) in 1999 (32). This definition is based on the assumption that 
insulin resistance is the major underlying risk factor for MetS. Evidence of insulin resistance 
and at least two other risk factors are required for the diagnosis. The WHO definition has 
been criticized, because it is difficult to measure insulin resistance by clamp techniques in 
clinical practice (38). Also, the use of waist-to-hip ratio as a measure of abdominal obesity 
as well as including microalbuminuria in the definition have been disputed. In the same 
year 1999 The European Group for The Study of Insulin Resistance further modified the 
definition of MetS (33). They used measurement of fasting plasma insulin for defining 
insulin resistance and waist circumference instead of waist-to-hip ratio for defining 
abdominal obesity. They also took out microalbuminuria from the definition and slightly 
modified different cut-off points. 
   In 2001 The National Cholesterol Education Program (NCEP) Adult Treatment Panel III 
published a more clinically ascertainable definition of MetS, which required the presence of 
three factors out of abdominal obesity as measured by waist circumference, impaired 
fasting plasma glucose or prevalent type 2 diabetes mellitus, elevated plasma triglycerides, 
reduced plasma high-density lipoprotein (HDL) cholesterol and elevated blood pressure 
(34). In 2003 the American Association of Clinical Endocrinology Position Statement 
provided less strict guidelines containing a list of traditional risk factors and additionally 
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other risk factors to be considered, allowing the diagnosis of “Insulin Resistance 
Syndrome” to rely on clinical judgment (35). In 2005 The International Diabetes Federation 
(IDF) attempted to develop a consensus definition that differed from the NCEP definition 
mainly in that abdominal obesity was made an obligatory component and was set at a 
lower level than in the The NCEP definition, with ethnic-specific cut-offs. However, The 
American Heart Association/National Heart, Lung, and Blood Institute (36) published their 
own definition of the MetS, with only minor differences from The NCEP definition. Thus, 
there was a need to reconcile these criteria in the form of harmonized Joint Statement by 
these associations and other major organizations. In this statement it was agreed that there 
should be no obligatory component for the diagnosis of MetS and that waist circumference 
would continue to be a preliminary screening tool (1). Three or more abnormal findings out 
of elevated waist circumference, elevated fasting glucose, elevated plasma triglycerides, 
reduced plasma HDL cholesterol and elevated blood pressure would qualify a person for 
the MetS. The categorical cut-off points were provided for all these components except for 
waist circumference, for which national and regional cut-off points should be used. The 
statement underlines the importance of using a commonly agreed-upon set of criteria to be 
used worldwide, with agreed-upon cut-off points for different ethnic groups and genders. 
     A syndrome can be defined as a clustering of factors that occur together more often than 
by chance alone and for which the cause is often uncertain, which holds true in the case of 
MetS (1,29). This idea of clustering of metabolic risk factors has been supported by studies 
using factor analysis, which can be used to reduce intercorrelated variables into a smaller 
set of factors and is a useful method for understanding patterns underlying the clustering 
of cardiometabolic risk factors (39). Exploratory factor analysis has traditionally been used 
to explore the possible underlying factor structure of a set of observed variables without 
imposing a preconceived structure on the outcome. Several previous studies have used 
exploratory factor analysis to examine the structure of MetS (40-44). The number of factors 
identified has ranged from 1 to 5. The results have ben inconsistent partly due different 
different variables or different numbers of variables being entered into the analyses or the 
manner of extraction or rotation used in the analyses (45). The promax rotation allows 
factors to be correlated, as opposed to the more commonly used varimax rotation, which 
generates uncorrelated factors (46). A previous study among adults by exploratory factor 
analysis found that second order factor analysis generated a single MetS factor that was 
loaded heavily by all three factors from the first-order analysis (10). CFA, on the other 
hand, is a technique testing a certain hypothesis (47). Recent studies using CFA have found 
a single factor underlying MetS in children (17), adolescents (48) and adults (49,50). The 
first-order CFA models for MetS used in previous studies are presented in Figure 1. 
Furthermore, Shen et. al. have used hierarchial a hierarchical CFA model with 10 measured 
variables in which the latent variables were allowed to covary (49).  
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  The clinical definitions of MetS are based on the dichotomization of risk factors. The 
dichotomization of continuous variables can be criticized because it reduces statistical 
power in the analyses. Moreover, the idea of dichotomization can also be criticized because 
there is no evidence for a clear threshold in risk factors above which cardiometabolic risk 
increases (51). A joint statement by the American Diabetes Association and The European 
Association for the Study of Diabetes has suggested further research in the use of 
continuous variables for the features of MetS in the definition of MetS (52). Using a 
continuous cardiometabolic risk score variable for the key features of MetS instead of a 
dichotomous variable for the syndrome has many advantages, especially for research. 
    The clustering of cardiometabolic risk factors and particularly the utility of the concept of 
MetS in a clinical context is an even greater matter of debate among children (12,17). 
Pediatric MetS has been defined using artificial and arbitrary cut-off points for its 
components based on the definitions of adulthood MetS (2,12). Such definitions are 
problematic, because the levels of cardiometabolic risk factors above which adverse health 
consequences start to occur among children are unknown. Difficulty to establish such 
criteria arouses from the complexity of the pediatric growth pattern and the effects of 
hormonal changes of puberty on body adiposity, insulin sensitivity and plasma levels of 
lipids and lipoproteins (11,12). Despite these difficulties concerning the diagnosis of MetS 
in children, The IDF has revealed guidelines for diagnosing MetS in children (53) based on 
previous studies (54-58) that used modified adult criteria to investigate the prevalence of 
MetS in children and adolescents (Table 1). According to the The IDF criteria, MetS should 
not be diagnosed in children under 10 years, but a strong message for weight reduction 
should be delivered for those with abdominal obesity (53). For children aged 10 to 16 years, 
MetS can be diagnosed by the presence of abdominal obesity and two or more other clinical 
features, including increased plasma glucose, elevated plasma triglycerides, reduced 
plasma HDL cholesterol or elevated blood pressure. For adolescents older than 16 years, 
the IDF adult criteria can be used (53). In children, the relatively low prevalence and the 
absence of a clear definition of the syndrome also support the use of a continuous 
cardiometabolic risk score (59). Previously used cardiometabolic risk scores calculated as 
the sum of z-score variables for MetS in children and adolescents are presented in Table 2. 
Another question is whether pediatric MetS can predict the risk of developing type 2 
diabetes or CVD in adulthood. Some epidemiological studies have shown that children 
with MetS have an increased risk of adulthood MetS, type 2 diabetes and CVD (5,6). 
However, the results of a recent study suggested that although MetS in youth predicts these 
chronic diseases it is not a better prognostic tool than simple body mass index (BMI) (60). 
Figure 1. The metabolic syndrome models used in previous studies using confirmatory factor analysis by 
Pladevall et.al. (42) (A), Li& Ford (40) (B) and Martinez-Vizcaino et.al. (17) (C). 
HDL= High-density lipoprotein cholesterol; HOMA-IR=Homeostatic model assessment for insulin 
resistance; MAP=Mean arterial pressure; MetS=metabolic syndrome; SBP=systolic blood pressure 
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Table 2. Cardiometabolic risk scores calculated as the sum of z-score variables in children and 
adolescents in previous studies 
 
Reference                                   Formula of the cardiometabolic risk score 
Ekelund et. al. 2007(61) waist circumference + ((systolic blood pressure + diastolic blood 
pressure)/2) + glucose + insulin - HDL cholesterol + triglycerides 
Eisenmann et. al. 2010 (14) waist circumference + mean arterial blood pressure + Homeostasis Model 
Assessment insulin resistance - HDL cholesterol + triglycerides 
Okosun et.al. 2010 (62) waist circumference + mean arterial blood pressure + glucose – HDL 
cholesterol + triglycerides 
 
2.1.2 Prevalence of metabolic syndrome 
The prevalence of MetS is increasing worldwide due to the epidemic of overweight in all 
age groups (29). The prevalence of MetS is rapidly increasing also in developing countries 
(63). The prevalence of MetS depends on the definitions used as well as the distribution of 
sex, age, race and ethnicity of the population studied. 
    According to The National Health and Examination Survey the age-adjusted prevalence 
of MetS in USA was 27.9% in 1988-1994 and 34.1% in 2003-2006. The prevalence of MetS in 
2003-2006 was found to increase with age so that it was 20% in men and 16% in women 
under 40 years of age, 41% in men and 37% in women between 40 and 59 years of age and 
52% in men and 54% in women 60 years and over (64). The same trend of a higher 
prevalence of MetS with advancing age has been observed in other populations (65). This 
increase seems to continue only up to sixth or seventh decade probably because individuals 
most susceptible to obesity-related mortality have likely died by this point (2,29). The 
difference between sexes in the prevalence of MetS varies across countries: in many 
countries there is very little difference in the prevalence of MetS between women and men, 
some countries have noticeably greater numbers of women than men who meet the MetS 
criteria, whereas others report a greater prevalence in men than in women (29). The 
prevalence of MetS in USA is also higher in African Americans than in Caucasians. The 
prevalence of MetS in Scandinavian adult populations has been similar to that of North-
Americans, which is approximately one-quarter of the populations (30). According to the 
National FINRISK study among 2049 Finns, MetS was present in 28.8% of men and in 
22.2% of women in 2004 (66). In the Young Finns study, the overall prevalence of MetS 
increased from 1.0% in 1986 to 7.5% in 2001 among adults 24 years of age (67). 
    Also the prevalence of childhood overweight and obesity is increasing globally, but the 
major problem with identifying the MetS in children and adolescents is that there are no 
established criteria for MetS in childhood or adolescence. In a recent review on the 
prevalence of pediatric obesity in 85 different studies during 2003-2013, the median 
prevalence of MetS was 3.3% in all populations combined, 11.9% in overweight children 
and 29.2% in obese children (68). The prevalence of MetS was higher in boys than in girls 
and also in older children than in younger children. Overweight and obesity were found to 
increase linearly in all sex and age groups from 1977 to 1999 among Finnish adolescents 12-
18 years of age (69). The age-standardized prevalence of overweight increased from 7.2% to 
16.7% in boys and from 4.0% to 9.8% in girls between 1977 and 1999, whereas the 
prevalence of obesity increased from 1.1% to 2.7% in boys and from 0.4% to 1.4% in girls 
during the 22-year follow-up. According to another study, 10% of boys and 18% of girls 
were overweight or obese at the age of 5 years in 2006 (70). At the age of 12 years, 24% of 
the boys and 19% of the girls were overweight or obese.  
 
7 
 
2.2 Causes of metabolic syndrome  
2.2.1 Genetic factors 
Several genome-wide scans performed in families with clustering of cardiometabolic risk 
factors have strongly supported an inherited component to MetS (71-73). In a study of 357 
children and 378 parents, children who had at least one parent with MetS, defined by The 
Adult Treatment Panel III criteria, had higher levels of obesity and insulin resistance than 
children in whom neither parent had MetS (74). Moreover, the Bogalusa Heart Study has 
shown that offspring of parents with early coronary heart disease were overweight 
beginning in childhood and developed an adverse cardiovascular risk factor profile at an 
increased rate (75). Also other family and twin studies have found strong familial 
aggregation for cardiometabolic risk factors (76-79). 
2.2.2 Low physical activity, sedentary behavior and poor cardiorespiratory fitness 
The current epidemic of overweight and MetS is mainly due to an imbalance between 
energy intake and energy expenditure. Low levels of physical activity increase the risk of 
MetS, type 2 diabetes, CVD and all-cause mortality in adults (80,81). The risk of developing 
these diseases can be reduced by increasing the levels of physical activity and 
cardiorespiratory fitness measured by maximal oxygen uptake (82-85). Low levels of 
physical activity and cardiorespiratory fitness have been associated with increased levels of 
independent and clustered metabolic risk factors also among adolescents and children 
(61,86-89). Habitual physical activity is progressively decreasing, whereas time spent in 
sedentary activities, such as watching TV and playing on computer, is increasing also 
among children in Finland (90). Sedentary lifestyle has resulted in a decline in 
cardiorespiratory and musculoskeletal fitness. However, the independent role and relative 
importance of physical activity and  sedentary in the development of childhood 
overweight, MetS and associated adverse health consequences as well as underlying 
biological mechanisms are still largely unknown.       
2.2.3 Dietary factors 
The role of diet in the development of MetS is not well understood. Western dietary pattern 
and the consumption of meat and fried foods have been directly related to the risk of MetS, 
whereas the consumption of whole-grain products, fruit, vegetables and dairy products 
have been inversely associated with it (91-93). Weight loss has been observed to be effective 
in the treatment of the components of MetS, including excessive body adiposity, insulin 
resistance, dyslipidemia and elevated blood pressure (94). The Finnish Diabetes Prevention 
Study revealed that even a modest weight loss reduced the prevalence of MetS in 522 
middle-aged overweight men and women with impaired glucose tolerance (95). The 
Diabetes Prevention Program in USA showed that an intensive lifestyle intervention 
reduced the incidence of MetS by 41% in among 3000 adults (96).  
   Also data on the role of dietary factors in the development of overweight and obesity 
among children are both limited and inconsistent (97,98). However, a high consumption of 
low-quality food, sugar-sweetened beverages, snacks and sweets, unfavorable meal 
patterns as well as emotional overeating and food responsiveness have been associated 
with overweight in children (99-101). Recent results from the Physical Activity and 
Nutrition in Children (PANIC) Study suggested that promoting a regular consumption of 
main meals, decreasing the consumptions of sugar-sweetened beverages and low-fat 
margarine and increasing the consumption of vegetable oils should be emphasized to 
reduce metabolic risk among children (101,102). 
2.2.4 Other factors 
Other potential risk factors underlying MetS might be epigenetic factors as well as 
overnutrition of fetus resulting in increased birth weight and low birth weight associated 
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with rapid catch-up growth (103-106). Exposure of the fetus to gestational diabetes of the 
mother increases the risk of MetS (107). Also cigarette smoking and excess alcohol 
consumption have been linked to increased cardiometabolic risk (108,109). Moreover, poor 
socioeconomic state and psychosocial background have been associated with MetS 
(110,111). Furthermore, health-related policy such as focus on early prevention plays 
fundamental role in reducing overweight and obesity and related clustering of 
cardiometabolic risk factors. 
2.3 The pathophysiology of metabolic syndrome 
2.3.1 Excess fat accumulation 
Long-term positive energy balance results in increased triglyceride storage in adipose tissue 
(112). In addition to adipocytes, adipose tissue constitutes of stromal fraction including pre-
adipocytes, fibroblasts, vascular cells and immune cells. Adipose tissue is mainly found in 
subcutaneous and visceral depots (113). The sites of ectopic fat accumulation include the 
muscle (114), liver (115), heart (116), pancreas (117) and the adventitia of blood vessels 
(118). Visceral adipose tissue has been associated with greater cardiometabolic risk 
compared to subcutaneous adipose tissue in all age groups (119-122). 
    Increased lipolysis in adipose tissue caused by adipose tissue insulin resistance results in 
increased plasma free fatty acid (FFA) levels which further disrupt lipid metabolism (123). 
The increased FFA flux impairs liver metabolism, leading to increased hepatic production 
of glucose and triglyceride-rich lipoproteins (124). Further, the elevated plasma levels of 
FFA also induce insulin resistance in the skeletal muscle by inhibiting insulin-mediated 
glucose uptake (125). Ectopic fat accumulation in the pancreas impairs β-cell function and 
thereby insulin secretion (126).  
   Recently, adipose tissue has emerged as an endocrine organ secreting hormones that 
regulate metabolism and appetite (127). It secretes a large number of proteins that modulate 
glucose metabolism and insulin action. Excess fat accumulation results in “bad talk” 
between adipocytes and immune cells and an increased secretion of numerous 
proinflammatory mediators like tumor necrosis factor alpha, interleukin-6 and C-reactive 
protein (CRP). Adipocytokines integrate the endocrine, autocrine and paracrine signals that 
mediate insulin sensitivity, oxidant stress, energy metabolism, blood coagulation, and 
inflammatory responses, which are thought to accelerate atherosclerosis, plaque rupture, 
and atherothrombosis (128). Moreover, metabolically dysfunctional adipose tissue is 
susceptible to adipocyte necrosis, contains M1-macrophages and impairs vascular function 
(129). Visceral adipose tissue has higher inflammatory activity compared to subcutaneous 
adipose tissue.  
   In addition to secretion of inflammatory mediators related to low-grade inflammation, 
excess fat accumulation results in increased secretion of several other adipokines such as 
leptin and decreased secretion of adiponectin (130). Leptin is involved in the regulation of 
satiety and hunger. Adiponectin regulates lipid and glucose metabolism, increases insulin 
sensitivity, regulates food intake and body weight, protects against a chronic inflammation 
and has antiatherogenic actions.  
2.3.2 Insulin resistance and hyperglycemia  
Insulin resistance is increased in overweight and obese individuals and is often seen as the 
core feature of MetS (113,131). The main physiologic effects of insulin include increase in 
skeletal muscle glucose uptake and suppression of hepatic glucose production and adipose 
tissue lipolysis (29). Insulin resistance is a general term meaning that insulin does not exert 
its normal effects in insulin-sensitive target tissues, such as skeletal muscle and adipose 
tissue (132).  
   As previously discussed, insulin resistance in adipose tissue manifests itself as the 
inability to suppress lipolysis, which leads to an influx of FFAs to the liver, skeletal muscle 
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and other organs leading to insulin resistance in these tissues (133). Also the large number 
of adipokines secreted by adipose tissue modulate insulin sensitivity (130). Insulin 
resistance in the liver increases gluconeogenesis and decreases glycogen synthesis resulting 
in fasting hyperglycemia (134). Insulin resistance in the liver and adipose tissue also drives 
the development of dyslipidemia, which is discussed in more detail in chapter 2.3.3. The 
majority of peripheral glucose uptake and further metabolism takes place in the skeletal 
muscle. Increased plasma FFA levels disrupt glucose-fatty acid cycle and insulin-mediated 
glucose uptake in the muscle (133). However, in nondiabetic state, this resistance is 
compensated by increased insulin secretion from the pancreatic β-cells. If pancreatic insulin 
secretion fails, insulin resistance in skeletal muscle increases hyperglycemia. The more 
insulin resistant a person, the more insulin must be secreted to prevent decompensation of 
glucose tolerance (135). If the compensatory mechanisms fail, the subsequent 
hyperglycemia and glucotoxicity will further worsen the insulin resistance and islet β-cell 
insulin secretion. Insulin resistance also further worsens the low-grade inflammatory state, 
induces endothelial dysfunction in the arteries and elevates blood pressure (132). Moreover, 
insulin resistance decreases signaling in the hypothalamus which leads to increased food 
intake and weight gain (136).  
2.3.3 Dyslipidemia 
It is currently unknown whether insulin resistance induces dyslipidemia or whether these 
risk factors are associated via a common underlying cause (12). Increased hepatic FA intake 
stimulated by insulin resistance leads to increased production of VLDL-triglycerides and 
apolipoprotein B. Apolipoprotein B is a marker of triglyceride-rich lipoproteins and retards 
triglyceride clearance (137). Increased liver fat content is associated with overproduction of 
VLDL from the liver due to lack of insulin-induced suppression of VLDL production (138). 
In addition to overproduction of VLDL by the liver, alterations in lipoprotein lipase activity 
have been associated with MetS (29). Moreover, circulating HDL cholesterol levels fall for 
sake of its overconsumption and the density of LDL increases in MetS. The small dense 
LDL is potentially atherogenic owing to its low affinity to the LDL receptor and long 
retention time in the circulation (29,139). 
2.3.4 Elevated blood pressure 
The role of blood pressure in the pathophysiology of MetS is not fully understood but 
several mechanisms have been suggested. Obesity has been associated with increased 
sympathetic tone which raises blood pressure (12). Furthermore, both insulin and leptin 
appear to increase sympathetic nervous activity. Also, in the setting of insulin resistance, 
the vasodilatory effect of insulin can be lost resulting in endothelial dysfunction and 
vasoconstriction (140). Moreover, hyperinsulinemia leads to increased sodium absorption 
in the kidneys that increases blood volume and thereby blood pressure (29,141). It has also 
been hypothesized that LDL cholesterol and triglycerides may damage the endothelium, 
impair nitric oxide release and cause endothelial dysfunction. This suggests that 
dyslipidemia could cause hypertension by mechanisms only partly related to obesity and 
insulin resistance (142,143). 
2.4 Consequences of metabolic syndrome 
2.4.1 Type 2 diabetes and its complications 
MetS is associated with a marked increase in risk for type 2 diabetes (1,7), which is 
characterized by chronically elevated blood glucose concentrations resulting from insulin 
resistance and reduced insulin secretion. A typical situation is relative insulin deficiency 
due to inability to adequately compensate for insulin resistance. Type 2 diabetes is a 
heterogeneous disease and its clinical expression requires both genetic and environmental 
factors (144). Nevertheless, most patients have insulin resistance and MetS before the onset 
 
10 
 
of type 2 diabetes (145). The progression of type 2 diabetes is preceded by overweight, 
obesity, insulin resistance and dyslipidemia in 75 to 85% of patients (29,144). The risk of 
CVD events is much higher in patients with type 2 diabetes than in non-diabetic subjects 
(146-148). Other common complications of type 2 diabetes include retinopathy, 
nephropathy and neuropathy, which also predict CVD (149-151). In recent years, also the 
prevalence of type 2 diabetes in children and adolescents has increased (152). Also, 
childhood MetS is known to predict type 2 diabetes (6). The main causes and consequences 
of MetS are presented in Figure 2.   
 
 
 
 
Figure 2. The main causes and consequences of metabolic syndrome        
 
2.4.2 Increased liver fat content 
NAFLD, recognized as the hepatic manifestation of the MetS (153,154), is rapidly becoming 
the most common chronic liver condition in many parts of the world and a major cause of 
liver-related morbidity and mortality. NAFLD includes histological spectrum of subtypes, 
ranging from simple steatosis (hepatic steatosis in the absence of histological evidence of 
hepatocellular damage) to NASH (steatosis with associated inflammation and hepatocyte 
damage with or without fibrosis). The clinical course of NAFLD depends upon its 
histological subtype; hepatic steatosis has generally a benign long-term prognosis whereas 
NASH can progress to cirrhosis with possible progression to end stage liver disease and 
hepatocellular carcinoma (155,156).  
  The pathophysiology of NAFLD is poorly understood but the “two-hit” hypothesis has 
been widely accepted (153). The first-hit, caused by insulin resistance leads to increased 
flux of FA from adipose tissue to the liver causing subsequent accumulation of triglycerides 
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in the hepatocytes. The “second-hit”, oxidative stress, activates inflammatory cytokines and 
generates reactive oxygen species which can cause cell injury and fibrosis due to formation 
of lipid peroxidation products. A liver containing excess fat is also insulin resistant and 
overproduces glucose and VLDL, which leads to hyperglycemia, hypertriglyceridemia, and 
a low HDL cholesterol concentration (153). In patients with MetS liver fat content has been 
found to be up to 4-fold higher than in those without MetS (115) and the incidence of 
NAFLD has been observed to be increased 4-fold in men and 11-fold in women with MetS 
(157). Also the other way round, NAFLD is a strong predictor of MetS (158). 
   The definitive diagnosis of NAFLD requires liver biopsy with evidence of fat with or 
without inflammation or fibrosis and minimal or no alcohol intake.  Presumptive diagnosis 
of NAFLD is based on elevated serum or plasma levels of liver enzymes aspartate 
aminotransferase, ALT and gamma-glutamyltransferase (GGT), or evidence of liver 
adiposity in ultrasonography, computed tomography or magnetic resonance imaging 
(MRI), minimal or no alcohol intake and negative results in examinations for viral hepatitis, 
congenital liver disease, autoimmune disease and other liver and biliary diseases (159). 
Among adults the prevalence of NAFLD ranges from 3% to 36% in the general population, 
depending on its screening method. The prevalence of NAFLD is particularly high among 
individuals with obesity (95%) and type 2 diabetes (50- 70%) (160). African Americans and 
Hispanics have a higher prevalence of NAFLD than other ethnic groups. Older age, 
diabetes, and obesity worsen the prognosis of NAFLD. Also genetic factors may play an 
important role.  
   The prevalence of NAFLD is increasing also in children and adolescents due to increased 
prevalence of overweight and obesity in these age groups (19). However, the true 
prevalence of NAFLD among children and adolescents is unknown and there are no 
established criteria for abnormal plasma ALT levels due to lack of population-based studies 
in children and adolescents (161). Study from autopsies of 742 children aged 2-19 years 
reported the prevalence of NAFLD to be 9.6% and in obese children this rate was 38% (162). 
Two-thirds of children with NAFLD have evidence of NASH on liver biopsy and are at risk 
for progressive liver disease (163). There is also evidence for a relationship between MetS 
and NAFLD among children. The presence of MetS was associated with severity of 
steatosis among Korean adolescents (164). Furthermore, a study among Italian children and 
adolescents showed that two thirds of those with NAFLD had MetS (165). Few previous 
studies have also found an association of MetS and its components even with high-normal 
levels of liver enzymes in children (166,167). Homeostatic model assessment (HOMA) 
insulin resistance was associated with GGT levels at reference range among overweight and 
obese Pima Indian children (166). Components of Mets and their clustering were associated 
with serum ALT levels at reference range among pre-adolescents and adolescents from 
Louisiana (167). Furthermore, Bogalusa Heart Study among young adults showed that 
high-normal values of ALT and GGT persisted over time and related to clinically relevant 
adverse cardiovascular risk profile (168). 
PNPLA3 gene variant and liver adiposity 
A genome-wide association study in a population of Hispanic, African American and 
European American adults showed that those with a cytosine-to-guanine (C→G) 
substitution (rs738409) that changes codon 148 from isoleucine to methionine in the 
adiponutrin/patatin-like phospholipase domain-containing 3 (PNPLA3) gene had an 
increased liver fat content and hepatic inflammation (24). The PNPLA3 gene is expressed in 
the liver and adipose tissue and the C→G substitution has been suggested to cause a loss of 
function of the PNPLA3 gene thereby limiting triglyceride hydrolysis in hepatocytes and 
promoting liver triglyceride accumulation (169,170). Thereafter, other studies have 
provided further evidence that the PNPLA3 gene I148M polymorphism is strongly 
associated with liver fat content and plasma ALT levels in obese adults and children (171-
174). Studies in obese adults and children have also suggested that the PNPLA3 gene I148M 
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variant is related to the severity of hepatic steatosis and the presence of NASH and fibrosis 
(174,175). The PNPLA3 148M allele has not been generally associated with the components 
of MetS, such as measures of body adiposity and lipid and and glucose metabolism 
(28,174,176,177). However, the results of some studies in children have suggested that the 
148M allele carriers have lower plasma levels of HDL cholesterol and a lower BMI than the 
non-carriers (28,176). It has been suggested that the increased amount of body fat may act 
as a stressor on the PNPLA3 148M carriers thereby influencing the susceptibility to 
increased circulating liver enzymes (25,177). 
   Studies related to the PNPLA3 gene polymorphism have been mostly carried out in obese 
patients with NAFLD and mainly in adult populations. Studies in obese children have 
shown that the PNPLA3 148M allele carriers have higher plasma ALT levels than the non-
carriers (177,178). One previous study in a Hispanic population, in which the PNPLA3 risk 
allele is most common, showed that the 148M allele was associated with increased plasma 
ALT levels not only in overweight or obese children but also in normal weight children 
(28). Two studies among children showed associations of the PNPLA3 gene I148M variant 
with hepatic fat content and the severity of NAFLD but no relationship to plasma ALT 
levels (174,179). The researchers speculated that lack of association with plasma ALT levels 
may have been due to small sample sizes. Evidence on the associations of the PNPLA3 gene 
polymorphism with measures of liver fat accumulation among children in previous studies 
are presented in Table 3. In general, more studies are needed to gain better understanding 
on the biological functions and pathogenetic mechanisms of this genetic variant with 
regard to liver adiposity (23). 
 
Table 3. The associations of the PNPLA3 I148M gene polymorphism with measures of liver fat 
accumulation among children in previous studies  
 
Reference                             Study population Association 
Larrietta-Carrasco et.al. 
2013 (28) 
1037 normal weight and 
overweight or obese Mexican 
children 
PNPLA3 148M allele was associated with 
increased ALT levels  
Giudice et.al. 2011 (177)            1048 obese Italian children or 
adolescents 
PNPLA3 148M allele was associated with 
 increased ALT levels 
Romeo et.al. 2010 (178)          475 overweight or obese Italian 
children and adolescents 
PNPLA3 148M allele was associated with  
increased ALT levels 
Santoro et.al. 2010 (179) 85 obese adolescents PNPLA3 148M allele was not associated 
with ALT levels but was related to  
higher hepatic fat content 
Valenti et.al. 2010 (174) 149 Italian children or 
adolescents with NAFLD 
PNPLA3 148M allele was not associated 
with ALT levels but was related to 
 the severity of NAFLD 
ALT=Alanine-amino transferase; NAFLD= Non-alcoholic fatty liver disease 
2.4.3 Atherosclerosis and atherosclerotic cardiovascular diseases 
In adults MetS has been strongly associated with subclinical atherosclerosis, as estimated 
by carotid artery intima-media thickness (IMT) (180) and atherosclerotic lesions using 
noninvasive ultrasonography (181,182). Previous studies have shown that cardiometabolic 
risk factors in childhood predict increased adult carotid IMT (183) as well as decreased 
carotid artery elasticity (184). Furthermore, cross-sectional studies have demonstrated that 
young adults aged around 30 years with MetS have increased IMT and decreased carotid 
artery elasticity (67). 
   MetS is associated with increased risk for CVD in next 5 to 10-years and the lifetime risk is 
undoubtedly higher (1). In the Atherosclerosis Risk in Communities study the risk for 
coronary heart disease over 11 years increased with the number of MetS components 
present (180). In another study also the amount of coronary calcification increased by the 
number of MetS risk factors (185). MetS has also been associated with increased risk of 
 
13 
 
acute ischemic stroke or transient ischemic attack. Individuals with MetS but without 
diabetes had a 1.5 times higher risk of ischemic stroke or transient ischemic attack 
compared with patients without MetS. This risk was higher in women than in men (186). In 
the KIHD study, middle-aged men without previous history of CVD were followed up for 
11 years, and those with MetS were three to four times more likely to die of coronary heart 
disease, about three times more likely to die of CVD and about two times more likely to die 
from all causes (10). Similar results have been found in other previous studies in Finland 
(187), USA (188), and the Netherlands (189).  
    Despite the predictive value of MetS for type 2 diabetes (7), CVD (8,9) and CVD as well 
as all-cause mortality (10) in adults, it still remains unclear, whether MetS has prognostic 
value over its individual components (52,190). Furthermore, the MetS is not an absolute risk 
indicator, because it does not contain many of the factors that determine absolute risk, for 
example, age, sex, cigarette smoking and low-density lipoprotein (LDL) cholesterol levels 
(1). 
2.4.4 Other manifestations of metabolic syndrome 
Other well-known manifestations of MetS include polycystic ovarian syndrome in women 
and obstructive sleep apnea (29). Polycystic ovarian syndrome is characterized by 
anovulation, androgen excess and insulin resistance (191). Women with polycystic ovarian 
syndrome have been found to have increased risk for developing type 2 diabetes and CVD. 
The pathophysiology of polycystic ovarian syndrome is unclear, but the ovary, 
hypothalamic-pituitary axis and insulin are likely to play a major role in it (192). 
Obstructive sleep apnea has been associated with excess body fat content, insulin resistance 
and other features of MetS (193,194). Moreover, individuals with obstructive sleep apnea 
are at increased risk for CVD morbidity and mortality (195). Several other disorders and 
symptoms such as dementia, depression, osteoarthritis, pulmonary embolism, gallbladder 
disease, asthma and many cancers have been associated with overweight and obesity (196-
198). 
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3 Aims 
The specific aims of the study were: 
 
1. to investigate the associations of the clustering of cardiometabolic risk factors as well 
as individual risk factors with plasma levels of liver enzymes ALT and GGT in 
prepubertal children (Study I). 
2. to validate the cardiometabolic risk score by confirmatory factor analysis in children, 
middle-aged men, and older women and men and by investigating the relationships 
of the cardiometabolic risk score to incident type 2 diabetes, myocardial infarction, 
and premature cardiovascular and overall death in middle-aged men (Study II). 
3. to investigate the associations of the I148M polymorphism of the PNPLA3 gene with 
plasma levels of ALT and GGT in normal weight and overweight children (Study 
III). 
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4 Methods 
4.1 Study populations and designs  
4.1.1 PANIC Study 
The Physical Activity and Nutrition in Children (PANIC) study is an ongoing exercise and 
diet intervention study in a population sample of children from the city of Kuopio, Finland 
(NCT01803776). Altogether 736 children 6-8 years of age who started the first grade in 
primary schools of Kuopio in 2007–2009 were invited to participate in the baseline 
examinations in 2007- 2009. Of the 736 invited children, 512 (70%) participated at baseline 
examinations and were divided in intervention and control groups. Families in the 
intervention group met an exercise specialist and an authorized nutritionist seven times 
during the first two years. The exercise specialist and the nutritionist gave the children and 
their parents detailed and individualized instructions on health promoting physical activity 
and diet at months 0, 1.5, 3, 6, 12, 18, and 24 with a specific topic at each visit. Altogether 
440 (86%) children took part also at 2-year follow-up examinations 2009-2011. A less 
intensive intervention in the intervention group will continue until adulthood. The 8-year 
follow-up will be performed in 2015-2017 and the 13-year follow-up in 2020-2022. The 
study protocol was approved by the Research Ethics Committee of the Hospital District of 
Northern Savonia. Both children and their parents gave their written informed consent.  
   The associations of the cardiometabolic risk score and single cardiometabolic risk factors 
with plasma levels of ALT and GGT in 492 prepubertal children with complete data on 
variables needed in the analyses were investigated in Study I (Table 4). Whether MetS 
represents a single entity in population samples of children, middle-aged men, older 
women and older men from Finland and whether the cardiometabolic risk score predicts 
the development of type 2 diabetes, myocardial infarction, ischemic stroke as well as 
premature CVD and total mortality during a long-term follow-up in middle-aged men were 
investigated in Study II. Altogether 491 children from PANIC study with complete data on 
variables needed for the analyses were included in the Study II. The associations of the 
I148M polymorphism in the PNPLA3 gene with plasma levels of ALT and GGT at baseline 
and with changes in plasma ALT and GGT levels during 2-year follow-up were studied 
among normal weight and overweight children in Study III. The final study population 
included 481 Caucasian children aged 6-8 years examined at baseline and 419 children re-
examined after 2-year follow-up with complete data on variables needed for the analyses. 
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Table 4. Study populations and designs 
 
 Participants Design 
The Physical Activity and 
Nutrition in Children Study 
  
Study I 492 children 
(232 girls, 260 boys) 
cross-sectional 
Study II 491 children 
(232 girls, 259 boys) 
cross-sectional 
Study III 481 children  
(227 girls, 254 boys) 
cross-sectional 
 407 children prospective 
   
The Kuopio Ischemic Heart 
Disease Risk Factor Study 
  
Study II 1900 men cross-sectional  
 790 men prospective (type 2 diabetes) 
 1209 men prospective (myocardial infarctions, 
ischemic strokes,  coronary deaths, 
cardiovascular deaths and deaths in total) 
The Dose-Responses to 
Exercise Training Study 
  
Study II 1169 individuals 
(614 women, 555 men) 
cross-sectional 
 
4.1.2 KIHD Study 
The Kuopio Ischemic Heart Disease Risk Factor (KIHD) study is an ongoing population 
study designed to investigate risk factors for CVD and related outcomes. The study 
population constituted a population sample of men who lived in the town of Kuopio or 
neighboring rural communities and who were 42, 48, 54, or 60 years of age at baseline 1984-
1989. Potential participants were randomly selected from the national population register. 
Of 3235 eligible men, 2682 (83%) participated in the study (10). The Research Ethics 
Committee of the Hospital District of Northern Savonia approved the study protocol. All 
participants gave their written informed consent. The final study population of Study II 
included 1900 middle-aged men from the KIHD Study with complete data on variables 
needed for the analyses after excluding those with a history of type 2 diabetes (Table 4). The 
follow-up data for type 2 diabetes were available for 790 men who participated in the 11-
year follow-up and had no type 2 diabetes at baseline.  The follow-up data for myocardial 
infarctions, ischemic strokes, coronary deaths, cardiovascular deaths and deaths were 
available in total for 1209 men after excluding men with history of type 2 diabetes, coronary 
heart disease, stroke or cancer. 
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4.1.3 DR’s EXTRA Study 
The Dose-Responses to Exercise Training (DR’s EXTRA) study is a 4-year randomized 
controlled trial on the health effects of regular physical exercise and diet (ISRCTN45977199, 
http://isrctn.org) in a population sample of 1476 men and women who were 57-78 years of 
age, lived in the city of Kuopio in Finland, participated in the baseline examinations in 
2005-2006 and were randomized into one of the six study groups at baseline (84). The study 
protocol was approved by The Research Ethics Committee of the Hospital District of 
Northern Savonia. All participants gave their written informed consent. The final study 
population of Study II included 614 older women and 555 older men from the DR’EXTRA 
Study with complete data on variables needed for the analyses after excluding those with a 
history of type 2 diabetes (Table 4). 
4.3 Assessments  
4.3.1 Assessments in the PANIC study 
Body fat percentage and body lean mass were assessed by the Lunar® dual energy X-ray 
absorptiometry (DXA) device (Lunar Prodigy Advance; GE Medical Systems, Madison, 
Wisconsin, USA) with the child empty-bladdered and lying in light clothing without metal 
objects. Body weight was assessed twice by the InBody® 720 bioelectrical impedance device 
(Biospace, Seoul, Korea) to accuracy of 0.1 kg after overnight fasting with the child empty-
bladdered and standing in light underwear. The mean of these two values of body weight 
was used in statistical analyses. Body height was assessed three times in the Frankfurt 
plane without shoes by a wall-mounted stadiometer to accuracy of 0.1 cm. The mean of the 
nearest two values was used in statistical analyses. BMI was calculated as body weight (kg) 
divided by body height (m) squared. BMI-SDS was computed by the Finnish references 
(199). Overweight and obesity were defined using the age- and sex- specific BMI cutoffs of 
the International Obesity Task Force (IOTF) criteria (200). Waist circumference was assessed 
three times after expiration at mid-distance between the bottom of the rib cage and the top 
of the iliac crest with an unstretchable measuring tape to accuracy of 0.1 cm. The mean of 
the nearest two values was used in statistical analyses. 
   The children were asked to fast for 12 hours before blood sampling. Biochemical analyses 
were done using Cobas 6000 analyzers (Hitachi High Technology Co, Tokyo, Japan). A 
hexokinase method was used to analyze plasma glucose (201) (Roche Diagnostics Co, 
Mannheim, Germany). Within and between day coefficients of variation (CV) for the 
glucose analyses were 0.7 – 0.9 % and 1.5 – 1.8 %, respectively.  Serum insulin was analyzed 
using electrochemiluminescence immunoassay with sandwich principle (202) (Roche 
Diagnostics Co). Within and between day CV for the insulin analyses were 1.3%–3.5 % and 
1.6%–4.4 %, respectively. A colorimetric enzymatic assay was used to analyze plasma total 
cholesterol and plasma triglycerides (203) (Roche Diagnostics Co). Within and between day 
CV for the cholesterol analyses were 1.0%-1.4 % and 1.2%–3.1% and for the triglyceride 
analyses 0.9%–4.2% and 1.4%–2.4%, respectively. Homogeneous enzymatic colorimetric 
assays were used to analyze HDL and LDL cholesterol (204,205) (Roche Diagnostics Co). 
Within and between day CVs for the HDL analyses were 1.1%–1.3% and 0.9%–1.2% and for 
the LDL cholesterol analyses were 1.3%–4.3 % and 1.7%–2.7%, respectively. Plasma high-
sensitivity hsCRP was measured using enhanced immuno-turbidimetric assay with CRP 
(Latex) High Sensitive Assay reagent (206) (Roche Diagnostics Co). The limit of detection 
was 0.15-0.20 mg/l. A kinetic method according to The International Federation of Clinical 
Chemistry was used to analyze plasma levels of ALT and GGT (207,208) (Roche Diagnostics 
GmbH Co). Within and between day CVs for the ALT analyses were 0.6%-1.6% (15 – 125 
U/l) and 1.3%–4.4% (42 – 136 U/l), respectively. The within and between day CVs for the 
GGT analyses were 0.0%–0.4% (15 – 201 U/l) and 1.0%–2.0 % (45 – 231 U/l), respectively. 
    Blood pressure was measured manually by a calibrated aneroid sphygmomanometer 
(HEINE GAMMA G7, Germany). The measurement protocol included, after a rest of five 
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minutes, three measurements in the sitting position at 2-minute intervals. The mean of all 
three values was used as the systolic and diastolic blood pressure in statistical analyses. 
  Habitual physical activity during a usual week was assessed by the PANIC Physical 
Activity Questionnaire administered by the parents at home. The types of physical activity 
included organized sports, structured exercise, unstructured physical activity, commuting 
to and from school and physical activity during recess. The frequency of each type of 
physical activity, expressed in sessions per week, and the duration of a single session of 
each type of physical activity were asked. The amount of each physical activity type was 
calculated by multiplying frequency with duration and was expressed in minutes per day. 
The amount of total physical activity was calculated by summing the amounts of each 
physical activity type and was expressed in minutes per day. All children in the first grade 
had 90 minutes of physical education per week that was added to the total physical activity. 
Habitual sedentary behavior during usual five weekdays and two weekend days was also 
assessed by the PANIC Physical Activity Questionnaire administered by the parents at 
home. The types of sedentary behavior included watching TV and videos, using a 
computer and playing video games and mobile games, listening to music, playing a 
musical instrument, reading, writing, drawing, doing arts and crafts, playing board games 
and sitting and lying. The amount of total sedentary behavior was calculated by summing 
the times spent in each sedentary behavior and was expressed in minutes per day weighted 
by the number of weekdays and weekend days. The PANIC Physical Activity 
Questionnaire was validated using the Actiheart monitor combining heart rate and 
accelerometry measurements (Actiheart, CamNtech, Cambridge, UK) in a subsample of 38 
children examined at baseline of the PANIC Study. Total physical activity measured by the 
questionnaire correlated positively with total physical activity measured by the Actiheart 
monitor (r=0.37, p=0.033). 
  Dietary intake was assessed by food records of four consecutive days that consisted of two 
weekdays and two weekend days (99.5% of children), or three weekdays and one weekend 
day (0.5% of children) (101). The parents were instructed to record all food and drink 
consumption of their children and to ask their children about their food consumption 
outside home. The schools and afterschool clubs were asked about the type and preparation 
of the served food. When the parents returned the records, clinical nutritionists checked the 
records and filled in missing information with them. The food records were analysed using 
the Micro Nutrica dietary analysis software (version 2.5, The Social Insurance Institution of 
Finland, Turku, Finland), with the food composition data from national analyses and 
international food composition tables (209). Vitamin and mineral supplements were not 
included in these analyses. Meals were defined by clinical nutritionists according to the 
recorded time and the type of food individually for each child, taking into account the 
whole meal pattern of the child.  
   The presence of chronic diseases and acute infections and the use of medications in 
children were assessed by a questionnaire administered by the parents. 
   The rs738409 polymorphism in the PNPLA3 gene was genotyped by a TaqMan probe 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s protocol. 
4.3.2  Assessments in the KIHD study 
Waist circumference was calculated as the average of two measurements taken after 
inspiration and expiration at the midpoint between the lowest rib and iliac crest. BMI was 
calculated as body weight (kg) divided by body height (m) squared.  
     The participants were asked to fast and to refrain from smoking for 12 hours and to 
avoid alcohol intake for three days before blood sampling. Blood glucose was measured 
using a glucose dehydrogenase method after precipitation of proteins by trichloroacetic 
acid. Fasting serum insulin was measured with a radioimmunoassay (RIA) (Novo Biolabs; 
Novo Nordisk, Bagsvaerd, Denmark). The between-batch CV was 8.9% at 9.1 mU/l and 
17.5% at 30.9 mU/l. At the follow-up, insulin was determined by RIA (Pharmacia 
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Diagnostics, Uppsala, Sweden). The between-batch CV was 6.7% at 14.5 mU/l and 5.4% at 
40.3 mUl. LDL and HDL fractions were separated from fresh serum by combined 
ultracentrifugation and precipitation. The cholesterol contents of serum lipoprotein 
fractions and triglycerides were measured enzymatically (Boehringer Mannheim, 
Mannheim, Germany). 
     Blood pressure was measured with a random-zero mercury sphygmomanometer. The 
mean of six measurements (3 while supine, 1 while standing, and 2 while sitting) of systolic 
and diastolic blood pressure was used.  
     Incident type 2 diabetes was defined as fasting blood glucose ≥6.1 mmol/liter or a clinical 
diagnosis of diabetes with either dietary, oral, or insulin treatment. All deaths and incident 
cardiovascular events were checked against hospital documents, health center wards and 
death certificates.  
     The use of blood pressure medication, smoking, alcohol consumption and 
socioeconomic status were assessed by a self-administered questionnaire. 
4.3.3 Assessments in the DR’s EXTRA study 
Waist circumference was calculated as the average of two measurements taken at mid-
distance between the bottom of the rib cage and the top of the iliac crest. BMI was 
calculated as body weight (kg) divided by body height (m) squared.  
     The participants were asked to fast and to refrain from smoking for 12 hours and to 
avoid exercise for one day and alcohol intake for three days before blood sampling. Plasma 
glucose was measured by a hexokinase method (Glucose, Thermo Clinical Labsystems Oy, 
Finland). Serum insulin was measured using ELISA kit (Mercodia, Uppsala, Sweden). 
Serum total cholesterol (Cholesterol, Thermo Electron Corporation, Finland) and serum 
triglycerides (Triglycerides, Thermo Electron Corporation, Finland) were analyzed by 
enzymatic photometric methods. Serum HDL cholesterol was analyzed using a direct 
enzymatic photometric method (HDL cholesterol, Thermo Electron Corporation, Finland). 
Serum LDL cholesterol was analyzed by a direct enzymatic photometric method (LDL-
Cholesterol, Thermo Electron Corporation, Finland). 
     Blood pressure was measured with a calibrated mercury sphygmomanometer or a desk 
aneroid sphygmomanometer in a sitting position after a 5-minute rest at 1-minute intervals 
and the mean of two consecutive measurements of systolic and diastolic blood pressure 
was used in statistical analyses. Incident type 2 diabetes was defined as fasting blood 
glucose ≥6.1 mmol/liter or a clinical diagnosis of diabetes with either dietary, oral, or insulin 
treatment. The use of blood pressure medication was assessed by a self-administered 
questionnaire. 
4.3.4 Cardiometabolic risk score 
A continuous cardiometabolic risk score variable was computed similarly to previously 
published scores (61) using continuous z-score variables by the following formula: waist 
circumference + insulin + glucose - HDL cholesterol + triglycerides + the mean of systolic 
and diastolic blood pressure. A higher score indicates a less favorable cardiometabolic risk 
profile. 
4.4 Statistical analyses 
Study I 
Before all statistical analyses variables were logarithmically transformed or square-root 
transformed to normalize skewed distributions if necessary. Differences in basic 
characteristics between sexes were compared by the independent samples t-test. 
Associations between the features of MetS were analyzed by partial correlations adjusted 
for age, sex and body height. The risk of having ALT and GGT in the highest fifth of their 
distributions in the sex-specific thirds of MetS and its components were analyzed using 
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binary logistic regression models after adjustment for age and body height. Because acute 
infections and chronic inflammatory diseases increase circulating hsCRP levels, only 
plasma hsCRP values below 10 mg/l were included in the analyses. Additional adjustments 
were also made for other components of MetS, body lean mass, physical activity, time spent 
on computer or watching TV as well as  the intake of saturated and unsaturated fatty acids. 
We also repeated these analyzes by excluding children with chronic diseases and 
medications which could increase liver enzymes.  
   The factor analyses were carried out entering waist circumference, fasting insulin, 
glucose, HDL cholesterol and triglycerides as well as systolic and diastolic blood pressure, 
which are generally considered the main features of MetS, as well as ALT, GGT and hsCRP, 
which were of particular interest, in the models. To normalize skewed distributions, natural 
logarithmic transformation for waist circumference, triglycerides, ALT, GGT and hsCRP 
and square root transformation for insulin was used. All variables were adjusted by age, 
sex and height before the factor analyses. The principal factor analysis was used for the 
extraction of the initial factors. Only factors with eigenvalues over 1.0, were retained in the 
analysis because these factors have more than one variable in it. The promax rotation that 
allows the variables to correlate with each other was used to assess possible underlying 
pathophysiological relationships. For the interpretation of the factors, variables having a 
correlation coefficient of ≥0.40 were considered to be heavily loaded and those having a 
correlation coefficient of 0.30–0.39 to be moderately loaded on the factors (10,143). 
Associations with a P-value of <0.05 were considered statistically significant. The statistical 
analyses were performed with the SPSS software for Windows, Version 19.0 (IBM SPSS 
Statistics, Chicago, IL, USA). 
 
Study II 
Before statistical analyses, continuous variables with skewed distributions were logarithmic 
or square-root transformed as appropriate. Differences in continuous variables between 
genders were analyzed with the independent samples t-test. The goodness of fit to the 
observed data was analyzed by χ2 tests, the comparative fit index (CFI), and the root mean 
square of approximation (RMSEA). 
   CFAs were carried out using continuous z score variables adjusted for age, sex and body 
height in the PANIC Study, for age group in the KIHD Study, and for age separately in 
women and men in the DR’s EXTRA Study. Second-order CFAs were also carried out in 
which the MetS was represented by a second-order latent variable underlying four latent 
variables characterized by adiposity, insulin resistance and glycaemia, dyslipidemia and 
raised blood pressure. These four latent variables in turn underlay eight measured 
variables used in the model: BMI, waist circumference, insulin, glucose, triglycerides, HDL 
cholesterol, systolic blood pressure and diastolic blood pressure. These second-order CFA 
models were similar in concept to the hierarchical CFA tested by Shen and coworkers (49). 
   Also first-order CFAs were carried out with models that have been used before (17,48,50). 
In the first model, proposed by Pladevall et al (50), the MetS was hypothesized to underlie 
abdominal obesity, insulin resistance, dyslipidemia and high blood pressure as represented 
by waist circumference, HOMA insulin resistance, the triglycerides to HDL cholesterol ratio 
and mean arterial pressure (MAP), respectively. In the second model, proposed by 
Martinez-Vizcaino et al (17), waist circumference, insulin, the triglycerides to HDL 
cholesterol ratio and MAP were included. In the third model, proposed by Li and Ford (48), 
waist circumference, insulin, triglycerides and systolic blood pressure were included. 
   The associations of the MetS factor and the cardiometabolic risk score with incident type 2 
diabetes during 11 years of follow-up in middle-aged men without diabetes at baseline 
were assessed with logistic regression models adjusted for age, family history of diabetes, 
prevalent CVD, smoking, alcohol intake and adult socioeconomic status. The relationships 
of the MetS factor and the cardiometabolic risk score with incident myocardial infarction, 
ischemic stroke as well as coronary, cardiovascular and total death in middle-aged men 
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were assessed with Cox proportional hazards regression models adjusted for age, family 
history of coronary heart disease, serum LDL cholesterol concentration, blood pressure 
medication, smoking, alcohol intake and adult socioeconomic status. The median follow-up 
time was 17.6 years for acute myocardial infarctions, 16.9 years for ischemic strokes and 
17.9 years for coronary, cardiovascular and total deaths. 
  Associations with a P-value of <0.05 were considered statistically significant. We used the 
SPSS Amos for Windows, Version 19 (Chicago, IL, USA) to perform the CFA. All other 
statistical analyses were performed with SPSS for Windows, Version 19.0. 
 
Study III 
Differences in basic characteristics between normal weight and overweight children were 
compared by the independent samples t-test. The Chi-Square test was used to verify 
whether the genotypes were in the Hardy-Weinberg equilibrium to find out if the observed 
genotype frequencies in the study population differ from the frequencies predicted by the 
equation (210). The associations of body fat percentage with plasma ALT and GGT levels 
were studied by linear regression analysis. Differences in plasma ALT and GGT levels 
among the genotypes were evaluated by the general linear models. General linear models 
were also used to test the determinants of plasma ALT and GGT levels. Data were adjusted 
for age, sex and body height. Data were additionally adjusted for waist circumference, 
clinical puberty, diseases and medications that could have effects on plasma ALT and GGT 
levels, the PANIC study group (intervention group versus control group), eating main 
meals regularly, the dietary intakes of carbohydrates, sucrose, and total, saturated, 
monounsaturated and polyunsaturated fat as percentages of energy intake, total physical 
activity and total sedentary behavior. Associations with a P-value of <0.05 were considered 
statistically significant. Statistical analyses were performed with the SPSS software for 
Windows, Version 19.0 (IBM SPSS Statistics, Chicago, IL, USA). 
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5 Results 
5.1 Associations of cardiometabolic risk factors with plasma levels of 
liver enzymes (Study I) 
Body height, waist circumference, glucose and HDL cholesterol were higher whereas body 
fat percentage, insulin, triglycerides and LDL cholesterol were lower among boys than girls 
(Table 5). Altogether 14.2 % of the girls and 10.4% of the boys were overweight or obese.   
 
    
Table 5.  Basic characteristics of children of the PANIC Study in Study I 
 
 
 All (n=492) Girls (n=232) Boys (n=260) P-valuea 
Age (years) 7.6 (0.4) 7.6 (0.4) 7.7(0.4) 0.217 
Body height (cm) 128.7 (5.7) 127.7 (5.6) 129.6 (5.6) <0.001  
Body weight (kg)  26.8 (4.9) 26.4 (5.0) 27.1 (4.8) 0.068 
Body mass index 16.1 (2.1) 16.1 (2.1) 16.1 (2.0) 0.850 
BMI-SDSb -0.20 (1.1) -0.18 (1.1) -0.22 (1.1) 0.643 
Waist circumference (cm) 56.6 (5.6) 55.9 (5.8) 57.2 (5.3) 0.006  
Body fat percentage (% 19.6 (8.2) 22.4 (7.6) 17.1 (7.8) <0.001 
Fasting serum insulin (mU/l) 4.5 (2.5) 4.8 (.3) 4.3(2.6) 0.010 
Fasting plasma glucose (mmol/l)  4.8 (0.4) 4.8 (0.4) 4.9 (0.4) 0.001  
Total cholesterol (mmol/l) 4.3 (0.6) 4.3 (0.6) 4.2 (0.6) 0.155 
LDL cholesterol (mmol/l) 2.4 (0.5) 2.4 (0.5) 2.3 (0.5) 0.033 
HDL cholesterol (mmol/l) 1.60 (0.31) 1.56 (0.31) 1.64 (0.31) 0.007 
Triglycerides (mmol/l) 0.59 (0.24) 0.62 (0.25) 0.58 (0.23) 0.038  
SBP (mmHg) 100.1 (7.3) 99.9 (7.6) 100.3 (7.1) 0.507 
DBP (mmHg)  61.8 (6.6) 61.6 (6.7) 62.0 (6.5)  0.495 
ALT (U/l) 18.5 (6.1) 18.1 (5.3) 18.9 (6.7) 0.143 
GGT (U/l) 11.7 (2.7) 11.6 (2.6) 11.8 (2.7) 0.397 
hsCRP (mg/l)  0.64 (0.93) 0.67 (0.84) 0.62 (0.62) 0.365 
Differences in means between girls and boys were analyzed with independent samples t-test. Data are 
presented as mean (standard deviation). 
ALT = alanine aminotransferase, GGT = gamma-glutamyltransferase; BMI-SDS = body mass index 
standard deviation score, based on Finnish reference values; DBP=diastolic blood pressure; LDL=low-
density lipoprotein; HDL= high-density lipoprotein; hsCRP=high-sensitivity C-reactive protein; 
SBP=systolic blood pressure 
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The risk of having ALT in the highest fifth of its distribution increased with increasing sex-
specific thirds of cardiometabolic risk score, body fat percentage, waist circumference and 
insulin adjusted for age and body height (Table 6). The risk of having GGT in the highest 
fifth of its distribution increased with increasing thirds of cardiometabolic risk score, body 
fat percentage, waist circumference, insulin, glucose and hsCRP adjusted for age and body 
height (Table 6). The associations of body fat percentage and waist circumference with ALT 
and GGT generally remained statistically significant after further adjustment for other 
components of MetS, except that the association of waist circumference with GGT was no 
longer statistically significant after adjustment for insulin (p=0.067). The relationships of 
other features of MetS generally were no longer associated with ALT and GGT after 
additional adjustment for fat percentage and waist circumference except that the 
association between fasting glucose and GGT remained even after controlling for body 
adiposity. Further adjustment for other features of MetS, body lean mass, total physical 
activity, time spent at computer and watching TV or the intake of saturated and 
unsaturated FA had little or no effect on these associations. Altogether 14.2 % of the girls 
and 10.4% of the boys were overweight or obese. Overweight or obese children had 2.1 
(95% confidence interval 1.2-4.0, P=0.016) times higher risk of having ALT in the highest 
fifth of its distribution and 4.5 (95% confidence interval 2.4-8.2, p<0.001) times higher risk of 
having GGT in the highest fifth of its distribution than normal-weight children.  
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  Table 6.  The risk of having alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT)  
  in the highest fifth of their distributions in sex-specific thirds of the cardiometabolic risk score and  
  related individual risk factors (n=492) 
 
 
 OR  (95% CI) of 
having ALT in the 
highest fifth  
p for 
trend 
OR  (95% CI) of 
having GGT in 
the      highest 
fifth 
p for 
trend 
Cardiometabo
lic risk score 
low  (girls <-1.5;  
boys <-1.9) 
1.0 (reference)  1.0 (reference)  
medium (girls -1.5-
0.9; boys -1.9-1.3)  
1.0  (0.6-1.9)  1.4 (0.8-2.7)  
high (girls >0.9;   
boys >1.3) 
1.8 (1.0-3.1) 0.048 2.6 (1.4-4.8) 0.002 
Body fat 
percentage 
low (girls <18.4;   
boys <12.3) 
1.0 (reference)  1.0 (reference)  
medium (girls 18.4-
24.2; boys 12.3-18.7) 
1.5 (0.8-2.9)  0.7 (0.3-1.3)  
high (girls >24.2;  
boys >18.7) 
2.9  (1.6-5.5)  2.3 (1.3-4.2) 0.004 
Waist 
circumference 
low  (girls < 53.3;  
boys < 54.3) 
1.0 (reference)  1.0 (reference)  
medium (girls 53.3-
56.6; boys 54.3-58.4) 
1.1 (0.6-2.0)  0.8 (0.4-1.4)  
high (girls >56.6;  
boys > 58.4) 
2.2 (1.2-4.1) 0.008 1.9 (1.0-3.5) 0.029 
Fasting serum 
insulin 
low  (girls < 3.7;    
boys <2.9) 
1.0 (reference)  1.0 (reference)  
medium (girls 3.8-5.5; 
boys 2.9-4.9) 
0.8 (0.5-1.5)  1.7 (0.9-3.2)  
high (girls >5.5;   
boys > 4.9) 
1.8 (1.0-3.0) 0.038 2.4 (1.3-4.4) 0.006 
Fasting 
plasma 
glucose 
low (girls < 4.7; 
boys<4.8) 
1.0 (reference)  1.0 (reference)  
medium (girls 4.7-4.8; 
boys 4.8-5.0) 
1.0 (0.6-1.7)  1.9 (1.0-3.6)  
high (girls ≥ 4.9;  
boys ≥ 5.1) 
0.8 (0.5-1.5) 0.558 2.5 (1.4-4.5) 0.003 
HDL 
cholesterol 
high (girls > 1.65; 
boys > 1.73) 
1.0 (reference)  1.0 (reference)  
medium (girls 1.45-
1.65; boys 1.49-1.73) 
1.0 (1.0-1.0)  1.25 (0.7-2.0)  
low (girls < 1.45;  
boys < 1.49) 
1.7 (0.9-2.5) 0.085 1.4 (0.8-2.5) 0.287 
Triglycerides low (girls < 0.47;  
boys < 0.46) 
1.0 (reference)  1.0 (reference)  
medium (girls 0.47-
0.64; boys 0.46-0.59) 
0.7 (0.4-1.2)  0.6 (0.3-1.1)  
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Data were analyzed by logistic regression models adjusted for age and body height.  
OR = odds ratio; 95% CI = 95% confidence interval; ALT = alanine aminotransferase, GGT = gamma-
glutamyltransferase; HDL = high-density lipoprotein; hsCRP= high-sensitivity C-reactive protein; SBP= 
systolic blood pressure 
 
    The features of MetS were generally intercorrelated. The first-order factor analysis with 
the promax rotation yielded three factors (Table 7). The first factor that explained the 
highest variance (24.9%) was heavily loaded by insulin, glucose and triglycerides. The 
second factor explaining 16.1% of the variance was highly loaded by waist circumference 
and insulin and moderately loaded by GGT and hsCRP. The third factor explaining 12.7 % 
of the variance was heavily loaded by HDL cholesterol and triglycerides and moderately by 
waist circumference and insulin. These three factors were intercorrelated (r=0.31-0.36, 
P<0.001). Factor analyses were also carried out using unadjusted variables and separately in 
boys and girls. The resulting factors had similar variances and loadings as those shown in 
Table 7. We therefore considered the sex differences negligible and performed the analyses 
in the entire cohort. 
 
 
  
high (girls > 0.64; 
boys > 0.59) 
0.8 (0.5-1.4) 0.890 1.3 (0.8-2.2) 0.303 
SBP low (girls < 96.1;  
boys <96.7) 
1.0 (reference)  1.0 (reference)  
medium (girls 96.1-
102.0; boys 96.7-
102.0) 
1.4 (0.8-2.6)  0.9 (0.5-1.7)  
high (girls > 102.0; 
boys >102.0) 
1.7 (1.0-3.1) 0.064 1.5 (0.8-2.6) 0.156 
hsCRP low (girls < 0.30;  
boys < 0.30) 
1.0 (reference)  1.0 (reference)  
medium (girls 0.30-
0.92; boys 0.30-0.95) 
1.3 (0.8-2.2)  1.4 (0.8-2.4)  
high (girls 0.93-6.60; 
boys 0.96-9.47) 
1.0  (0.5-2.0) 0.711 2.5 (1.4-4.6) 0.004 
Table 6.continues 
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Table 7.  Structure matrix and factor intercorrelations for the factor analysis of the 
traditional features of the metabolic syndrome as well as alanine aminotransferase, 
gamma-glutamyltransferase and high-sensitivity C-reactive protein using the promax 
rotation (n=492) 
 
 Insulin resistance 
factor 
Abdominal and 
liver adiposity 
factor 
Dyslipidemia  
factor 
Waist circumference 0.23 0.80 0.35 
Fasting insulin 0.80 0.43 0.35 
Fasting glucose 0.67 0.06 0.14 
HDL cholesterol -0.17 -0.16 -0.61 
Triglycerides 0.50 0.16 0.47 
Mean of SBP and DBP 0.19 0.26 -0.03 
ALT -0.03 0.28 -0.13 
GGT 0.17 0.34 0.08 
hsCRP 0.07 0.38 0.16 
All variables were adjusted for age, sex and body height before factor analysis with log transformation or 
square root transformation, if necessary. ALT = alanine aminotransferase, GGT = gamma-glutamyltransferase 
DBP=diastolic blood pressure; HDL= high-density lipoprotein; hsCRP=high-sensitivity C-reactive protein; 
SBP=systolic blood pressure 
 
The second-order factor analysis that used the three factors generated from the first-order 
factor analysis yielded a MetS factor (Table 8). All three factors from the first-order factor 
analysis had high loadings on the MetS factor that explained 64.1% of the variance. This 
MetS factor was almost the equivalent of the composite cardiometabolic risk score that was 
calculated as the sum of the individual standardized variables (r=0.91).  
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Table 8.  Correlations of the MetS factor from the second- order factor analysis with 
the three factors from the first-order factor analysis shown in Table 7 and the 
cardiometabolic risk score    
 
                             MetS factor        
Insulin resistance factor  0.66              
Abdominal and liver adiposity 
factor 
 0.61              
Dyslipidemia factor  0.77              
Cardiometabolic risk score  0.91              
 
Also the first-order factor analysis with traditional features of Mets without ALT, GGT and 
hsCRP with a promax rotation yielded three factors (Table 9). The first factor explaining the 
highest proportion of the variance (35.0%) was heavily loaded by insulin, glucose and 
triglycerides. The second factor (18.3%) had high loadings by HDL cholesterol, triglycerides 
and a moderate loading by waist circumference. The third factor (17.0%) had high loadings 
by waist circumference and insulin. 
 
 
 
Table 9. Structure matrix and factor intercorrelations for the factor analysis of the traditional 
features of the metabolic syndrome using the promax rotation (n=492) 
 
 Insulin 
resistance 
factor 
Dyslipidemia 
factor 
Abdominal  
adiposity 
 factor 
 
Waist 0.23 0.31 0.72    
Insulin 0.81 0.28 0.54    
Glucose 0.67 0.08 0.16    
HDL cholesterol -0.17 - 0.75 -0.25    
Triglycerides 0.49 0.40 0.27    
(SBP + DBP)/2 0.20 - 0.01 0.25    
All variables were adjusted for age, sex and body height before factor analysis with log transformation or 
square root transformation, if necessary. DBP= diastolic blood pressure; HDL= high-density lipoprotein;  
SBP=systolic blood pressure; TG=triglycerides 
 
All factors had high loadings on the second-order MetS factor (Table 10). Also, the second-
order MetS factor was essentially the equivalent of the cardiometabolic risk score (r=0.87).  
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Table 10. Correlations of the MetS factor from the second-order factor analysis with the 
three factors from the first-order factor analysis shown in Table 9 and the 
cardiometabolic risk score (n=492) 
 
                                MetS factor 
Insulin resistance factor 0.65  
Dyslipidemia factor 0.58  
Abdominal adiposity factor 0.90  
Cardiometabolic risk score 0.87  
 
5.2 Validation of cardiometabolic risk score by confirmatory factor 
analysis in children and adults and the prediction of cardiometabolic 
outcomes in adults (Study II) 
The basic characteristics of participants in PANIC, KIHD and DR’s EXTRA studies in Study 
II are presented in Table 11. 
 
Table 11. Basic characteristics of participants in the PANIC, KIHD and DR’s EXTRA studies in 
Study II 
 
Differences in means between genders were analysed with independent samples t test. Data are presented 
as mean (standard deviation). DBP=diastolic blood pressure; HDL= High-density lipoprotein; SBP=systolic 
blood pressure 
 
The features of MetS were generally intercorrelated in girls and boys, in middle-aged men 
and in older women and men (Tables 12-15). All features of MetS showed moderate to 
strong correlations with the composite cardiometabolic risk score (r=0.30–0.76) and the 
MetS factor variable derived from the second-order CFA (r=0.24–0.88) described below. 
 
 
 
  PANIC            KIHD                     DR’EXTRA 
Girls  
(n=232) 
Boys  
(n=259) 
 p-value Middle-aged 
men 
 (n=1900) 
 Older 
women 
(n=614) 
Older men 
(n=555) 
p value 
Age (years) 7.6 (0.4) 7.7 (0.4)  0.206 52.7 (5.7)  66.5 (5.3) 66.3 (5.5) 0.487 
Height (cm) 127.7 (5.6) 129.6 (5.6)  <0.001 173.0 (6.2)  160.0 (5.9) 173.7 (6.1) <0.001 
Body weight (kg) 26.4 (5.0) 27.1 (4.8)  0.107 80.2 (11.7)  69.6 (12.3) 82.4 (12.6) <0.001 
BMI 16.1 (2.1) 16.1 (2.0)  0.791 26.8 (3.4)  27.2 (4.6) 27.3 (3.5) 0.833 
Waist 
circumference 
(cm) 
55.9 (5.8) 57.2 (5.3)  0.015 90.7 (9.6)  87.6 (12.0) 97.8 (10.1) <0.001 
Fasting insulin 
(mUl/l) 
4.8 (2.3) 4.3 (2.6)  0.021 11.1 (6.5)  6.9 (4.5) 7.3 (5.0) 0.180 
Fasting glucose 
(mmol/l) 
4.8 80.4) 4.9 (0.4)  0.001 4.6 (0.5)  5.5 (0.5) 5.8 (0.5) <0.001 
Total cholesterol 
(mmol/l) 
4.3 (0.6) 4.2 (0.6)  0.147 5.8 (1.0)  5.3 (0.9) 5.0 (0.9) <0.001 
LDL-cholesterol 
(mmol/l) 
2.4 (0.5) 2.3 (0.5)  0.013 4.0 (1.0)  3.3 (0.8) 3.2 (0.8) 0.490 
HDL cholesterol 
(mmol/l) 
1.56 (0.31) 1.64 (0.31)  0.007 0.86 (0.29)  1.88 (0.47) 1.54 (0.41) <0.001 
Triglycerides  
(mmol/l) 
0.62 (0.25) 0.58 (0.23)  0.064 1.31 (0.78)  1.27 (0.62) 1.36 (0.74) 0.029 
SBP (mmHg) 99.9 (7.6) 100.2 (7.1)  0.565 132.5 (16.3)  149.8 (20.8) 144.8 (18.4) <0.001 
DBP (mmHg) 61.6 (6.7) 62.0 (6.5)  0.536 88.2 (10.4)  82.5 (9.1) 84.5 (8.9) <0.001 
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Table 12. Intercorrelations of features of MetS in 491 children 6-8 years of age 
 
Correlation BMI Waist Insulin Glucose HDL  TG TG/HDL SBP DBP MAP 
Waist 0.92          
Insulin 0.34 0.33         
Glucose 0.05 0.05 0.52        
HDL cholesterol -0.16 -0.21 -0.17 -0.04       
TG 0.13 0.14 0.40 0.29 -0.29      
TG/HDL cholesterol 0.18 0.21 0.39 0.24 -0.65 0.92     
SBP 0.15 0.11 0.13 0.07 0.03 0.12 0.08    
DBP 0.16 0.15 0.15 0.11 0.03 0.08 0.05 0.28   
MAP 0.19 0.16 0.17 0.11 0.04 0.11 0.08 0.64 0.92  
MetS score 0.52 0.55 0.76 0.59 -0.50 0.66 0.74 0.30 0.32 0.38 
MetS factor 
(second-order CFAa) 
0.31 0.31 0.84 0.57 -0.28 0.81 0.76 0.25 0.24 0.29 
MetS factor (first-
order CFAb) 
0.50 
 
0.52 0.93 0.54 -0.34 0.60 0.62 0.21 0.25 0.29 
MetS factor (first-
order CFAc) 
0.52 0.53 0.94 0.47 -0.34 0.58 0.60 0.21 0.25 0.28 
MetS factor (first-
order CFAd) 
0.42 0.43 0.98 0.51 -0.21 0.52 0.50 0.19 0.17 0.28 
For r >[0.08], p <0.05; for r >[0.12], p<0.01; for r >[0.15], p<0.001. 
All variables have been adjusted by age, sex and height before analysis. 
DBP=diastolic blood pressure; TG=triglycerides; SBP=systolic blood pressure; Waist=waist circumference 
aMetS as a second-order latent variable underlying the first-order latent factors adiposity, insulin 
resistance and glycaemia, dyslipidaemia and raised blood pressure, with BMI, waist, insulin, glucose, HDL 
cholesterol, TG, SBP and DBP as measured variables (our model, Figure 3) 
bCFA carried out with waist, HOMA-IR, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Pladevall et. al) (50) 
cCFA carried out with waist, insulin, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Martinez-Vizcaino et. al.)  (17) 
dCFA carried out with waist, insulin, TG and SBP as measured variables (model proposed by Li and Ford) 
(48) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
30 
 
Table 13. Intercorrelations of features of MetS in 1900 men 42-60 years of age 
 
Correlation BMI Waist Insulin Glucose HDL  TG TG/HDL SBP DBP MAP 
Waist 0.89          
Insulin 0.56 0.56         
Glucose 0.27 0.27 0.32        
HDL cholesterol -0.23 -0.24 -0.27 -0.05       
TG 0.30 0.29 0.36 0.13 -0.37      
TG/HDL cholesterol 0.32 0.32 0.39 0.12 -0.66 0.94     
SBP 0.27 0.26 0.19 0.12 0.03 0.11 0.08    
DBP 0.35 0.35 0.23 0.14 -0.03 0.13 0.11 0.76   
MAP 0.33 0.33 0.23 0.14 0.00 0.12 0.10 0.92 0.95  
MetS score 0.70 0.73 0.75 0.52 -0.53 0.62 0.69 0.44 0.50 0.50 
MetS factor (second- 
order CFAa) 
0.88 0.88 0.83 0.39 -0.35 0.48 0.51 0.34 0.44 0.42 
MetS factor (first-
order CFAb) 
0.82 
 
0.87 0.86 0.41 -0.35 0.49 0.52 0.35 0.43 0.42 
MetS factor (first-
order  CFAc) 
0.81 0.87 0.87 0.33 -0.37 0.50 0.54 0.34 0.42 0.41 
MetS factor (first-
order CFAd) 
0.78 0.83 0.90 0.33 -0.32 0.51 0.53 0.33 0.38 0.38 
For r >[0.04], p<0.05; for r>[0.05], p<0.01; for r>[0.07], p<0.001.  
All variables have been adjusted by age before analysis. 
DBP=diastolic blood pressure; TG=triglycerides; SBP=systolic blood pressure; Waist=waist circumference 
aMets as a second-order latent variable underlying the first-order latent factors adiposity, insulin resistance 
and glycaemia, dyslipidaemia and raised blood pressure, with BMI, waist, insulin, glucose, HDL cholesterol, 
TG, SBP and DBP as measured variables (our model, Figure 3) 
bCFA carried out with waist, HOMA-IR, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Pladevall et. al) (50) 
cCFA carried out with waist, insulin, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Martinez-Vizcaino et. al.) (17) 
dCFA carried out with waist, insulin, TG and SBP as measured variables (model proposed by Li and Ford) 
(48) 
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Table 14. Intercorrelations of features MetS in 614 women 57-78 years of age 
 
Correlation BMI Waist Insulin Glucose HDL  TG TG/HDL SBP DBP MAP 
Waist 0.90          
Insulin 0.50 0.51         
Glucose 0.33 0.34 0.38        
HDL cholesterol -0.30 -0.37 -0.31 -0.18       
TG 0.29 0.36 0.37 0.20 -0.48      
TG/HDL cholesterol 0.33 0.41 0.40 0.22 -0.77 0.93     
SBP 0.18 0.16 0.03 0.08 -0.02 0.07 0.06    
DBP 0.25 0.24 0.06 0.04 -0.07 0.12 0.12 0.62   
MAP 0.23 0.22 0.05 0.06 -0.05 0.11 0.10 0.91 0.89  
MetS score 0.69 0.71 0.71 0.49 -0.65 0.66 0.73 0.30 0.41 0.40 
MetS factor (second-
order CFAa) 
0.88 0.88 0.83 0.39 -0.35 0.48 0.51 0.34 0.44 0.42 
MetS factor (first-
order  CFAb) 
0.81 
 
0.89 0.86 0.44 -0.52 0.59 0.65 0.18 0.25 0.24 
MetS factor (first-
order CFAc) 
0.81 0.90 0.87 0.40 -0.53 0.59 0.65 0.18 0.25 0.24 
MetS factor (first-
order CFAd) 
0.80 0.88 0.90 0.41 -0.46 0.60 0.62 0.17 0.22 0.21 
For r>[0.09], p<0.05; for r>[0.11], p<0.01; for r>[0.13], p<0.001.  
All variables have been adjusted by age before analysis. 
DBP=diastolic blood pressure; TG=triglycerides; SBP=systolic blood pressure; Waist=waist circumference 
aMets as a second-order latent factor underlying the first-order latent factors adiposity, insulin resistance 
and glucose metabolism, dyslipidemia, and blood pressure, with BMI, waist, insulin, glucose, HDL 
cholesterol, TG, SBP and DBP as measured variables (our model, Figure 3) 
bCFA carried out with waist, HOMA-IR, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Pladevall et. al) (50) 
cCFA carried out with waist, insulin, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Martinez-Vizcaino et. al.) (17)   
dCFA carried out with waist, insulin, TG and SBP as measured variables (model proposed by Li and Ford) 
(48) 
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Table 15. Intercorrelations of features of MetS in 555 men 57-78 years of age 
 
Correlation BMI Waist Insulin Glucose HDL  TG TG/HDL SBP DBP MAP 
Waist 0.90          
Insulin 0.45 0.46         
Glucose 0.26 0.25 0.31        
HDL cholesterol -0.34 -0.33 -0.33 -0.11       
TG 0.33 0.33 0.34 0.07 -0.55      
TG/HDL cholesterol 0.38 0.37 0.39 0.10 -0.80 0.94     
SBP 0.11 0.10 0.06 0.05 0.03 0.04 0.01    
DBP 0.24 0.26 0.14 0.02 -0.05 0.12 0.10 0.57   
MAP 0.20 0.20 0.11 0.04 -0.01 0.09 0.06 0.89 0.88  
MetS score 0.68 0.75 0.70 0.58 -0.64 0.67 0.76 0.34 0.38 0.40 
MetS factor (second- 
order CFAa) 
0.88 0.88 0.83 0.39 -0.35 0.48 0.51 0.34 0.44 0.42 
MetS factor (first-
order CFAb) 
0.78 
 
0.83 0.82 0.34 -0.55 0.60 0.65 0.16 0.29 0.25 
MetS factor (first-
order CFAc) 
0.78 0.82 0.82 0.30 -0.55 0.60 0.66 0.15 0.29 0.25 
MetS factor (first-
order CFAd) 
0.77 0.82 0.84 0.30 -0.48 0.60 0.63 0.14 0.26 0.22 
For r>[0.09], p<0.05; for r>[0.11], p<0.01; for r>[0.15], p<0.001. 
All variables have been adjusted by age before analysis.  
DBP=diastolic blood pressure; TG=triglycerides; SBP=systolic blood pressure; Waist=waist circumference 
aMets as a second-order latent factor underlying the first-order latent factors adiposity, insulin resistance 
and glucose metabolism, dyslipidemia, and blood pressure, with BMI, waist, insulin, glucose, HDL 
cholesterol, TG, SBP and DBP as measured variables (our model, Figure 3) 
bCFA carried out with waist, HOMA-IR, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Pladevall et. al) (50) 
cCFA carried out with waist, insulin, TG/HDL cholesterol ratio and MAP as measured variables (model 
proposed by Martinez-Vizcaino et. al.) (17)   
dCFA carried out with waist, insulin, TG and SBP as measured variables (model proposed by Li and Ford) 
(48) 
 
    Figure 3 presents the second-order CFA models in which a latent MetS variable underlies 
four latent variables—abdominal obesity, insulin resistance, dyslipidemia and raised blood 
pressure—which are in turn manifested by eight measured features of MetS in different age 
groups. These results indicate that MetS can be described as a single entity in the four age 
groups. The second-order CFAs with the latent variables generally fitted the data well in all 
cohorts. In children, the model resulted in loading >1 for BMI on the latent adiposity 
variable, and the model was modified by allowing the latent adiposity variable to also load 
on insulin. In older men, the analysis resulted in loading >1 for diastolic blood pressure on 
the latent raised blood pressure variable, and the model was modified by using MAP and 
blood pressure medication instead of systolic blood pressure and diastolic blood pressure. 
In older men without antihypertensive medication, the model could be presented without 
these modifications (Figure 4). 
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Figure 3. Second-order confirmatory analysis models in 491 children, 1900 middle-aged men, 614 older women
and 555 older men. BMI=body mass index; BP med= blood pressure medication: CFI=comparative fit index; 
DBP=diastolic blood pressure; IRG=insulin resistance and glycemia;  MAP= mean arterial pressure, 
MetS=metabolic syndrome; SBP=systolic blood pressure;  TG=triglycerides; RMSEA=root mean square of 
approximation
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MetS
Adiposity
IRG
Lipids
Blood 
pressure
BMI
Insulin
Glucose
TG
HDL
SBP
DBP
Waist
0.93
0.73
0.84
0.96
0.81
0.39
0.74
-0.73
0.58
0.97
0.62
0.30
 
Figure 4. Second-order confirmatory factor analysis model in 349 older men without antihypertensive 
medication. Goodness of fit: χ2=321.1, p=0.17, comparative fitness index (CFI)=1.00, root mean of 
approximation (RMSEA)=0.030. DBP= diastolic blood pressure; IRG=insulin resistance and glycaemia; 
MetS=metabolic syndrome; SBP=systolic blood pressure; TG=triglycerides  
 
   Tables 16–18 present comparisons of three previously proposed first-order CFA models 
hypothesizing that a latent MetS underlies four variables: abdominal obesity, insulin 
resistance, dyslipidemia and raised blood pressure. A first-order CFA using the model 
proposed by Pladevall et al yielded a MetS factor with loadings on waist circumference of 
0.43, 0.76, 0.77 and 0.69, on HOMA measured insulin resistance of 0.76, 0.75, 0.69 and 0.69, 
on the triglycerides to HDL cholesterol ratio of 0.51, 0.46, 0.56 and 0.54, and on MAP of 0.24, 
0.36, 0.21 and 0.21 in children, middle-aged men, older women and older men, respectively 
(Table 16). The CFA model proposed by Martinez-Vizcaino et al yielded a MetS factor 
essentially identical with that using HOMA-measured insulin resistance instead of insulin, 
with almost identical loadings in all four cohorts (Table 17). The CFA model proposed by Li 
and Ford also yielded a similar MetS factor, with slightly less loading on waist 
circumference (0.38), dyslipidemia (0.46) and blood pressure (0.17) and more loading on 
insulin (0.87) in children, and less loading on blood pressure in middle-aged men (0.29), 
older women (0.14) and older men (0.11) (Table 18). As estimated by CFI, all three models 
fitted the data well in all four cohorts (0.97–0.97). As judged by the RMSEA, however, fit 
was not good in middle-aged men and older women (0.104–0.110) in the two models using 
the triglycerides to HDL cholesterol ratio and MAP as measures of dyslipidemia and high 
blood pressure.  
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Table 16. The results of the first-order confirmatory factor analysis model of Pladevall et al 
(50) using four variables describing the central features of metabolic syndrome in children, 
middle-aged men, older women and older men 
     
Variable MetS factor, MetS factor, MetS factor, MetS factor, 
 children 
(n=491) 
middle-aged 
men 
(n=1900) 
older women 
(n=614) 
older men   
(n=555) 
Waist circumference 0.43 0.76 0.77 0.69 
HOMA-insulin resistance 0.76 0.75 0.69 0.69 
Triglycerides to HDL cholesterol ratio 0.51 0.46 0.56 0.54 
Mean arterial pressure 0.24 0.36 0.21 0.21 
 
Goodness of fit for the model in children: χ2=4.40, p=0.110, CFI=0.99, RMSEA=0.049 
Goodness of fit for the model in middle-aged men: χ2=43.1, p<0.001, CFI=0.97, RMSEA=0.104 
Goodness of fit for the model in older women: χ2=15.6, p<0.001, CFI=0.97, RMSEA=0.105 
Goodness of fit for the model in older men: χ2=6.05, p=0.049, CFI=0.99, RMSEA=0.060 
 
Table 17. The results of the first-order confirmatory factor analysis model of Martinez-Vizcaino 
et al (17) using four variables describing the central features of metabolic syndrome in children, 
middle-aged men, older women and older men  
 
Variable MetS 
factor, 
children 
(n=491) 
MetS factor, 
middle-aged 
men 
(n=1900) 
MetS factor, 
older women 
(n=614) 
MetS factor, 
older men 
(n=555) 
Waist circumference 0.44 0.75 0.77 0.69 
Fasting insulin 0.77 0.75 0.67 0.68 
Triglycerides to HDL cholesterol ratio 0.50 0.46 0.56 0.55 
Mean arterial pressure 0.24 0.36 0.21 0.21 
 
Goodness of fit for the model in children: χ2=4.00, p=0.140, CFI=0.99, RMSEA=0.049 
Goodness of fit for the model in middle-aged men: χ2=50.2, p<0.001, CFI=0.96, RMSEA=0.110 
Goodness of fit for the model in older women: χ2=16.7, p<0.001, CFI=0.96, RMSEA=0.109 
Goodness of fit for the model in older men: χ2=6.42, p=0.040, CFI=0.98, RMSEA=0.063 
 
Table 18. The results of the first-order confirmatory factor analysis model of Li and Ford (48) 
using four variables describing the central features of metabolic syndrome in children, middle-
aged men, older women and older men  
 
 
 
Variable 
MetS 
factor, 
children 
(n=491) 
MetS factor, 
middle-aged 
men 
(n=1900) 
MetS factor, 
older women 
(n=614) 
MetS factor, 
older men 
(n=555) 
Waist circumference 0.38 0.72 0.74 0.67 
Fasting insulin 0.87 0.78 0.69 0.69 
Triglycerides 0.46 0.44 0.51 0.49 
Systolic blood pressure 0.17 0.29 0.14 0.11 
 
Goodness of fit for the model in children: χ2=3.62, p=0.160, CFI=0.99, RMSEA=0.041 
Goodness of fit for the model in middle-aged men: χ2=25.2, p<0.001, CFI=0.98, RMSEA=0.078 
Goodness of fit for the model in older women: χ2=11.2, p=0.004, CFI=0.98, RMSEA=0.087 
Goodness of fit for the model in older men: χ2=0.93, p=0.630, CFI=1.00, RMSEA=0.00 
 
     Correlations of the cardiometabolic risk score with MetS factors derived from the 
second-order CFA and first-order CFAs including the triglycerides to HDL cholesterol ratio 
and MAP were very similar (r=0.90–0.93 depending on the cohort), but the correlation with 
that derived from the first-order CFA using systolic blood pressure was slightly weaker in 
children (r=0.84) (Table 19). 
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Table 19. The correlations of cardiometabolic risk score and metabolic syndrome factors 
derived from confirmatory factor analyses of previous studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aOur second-order CFA-model as presented in Fig.4 
bModel proposed by Pladevall et al (50) 
cModel proposed by Martinez-Vizcaino et al (17) 
dModel proposed by Li and Ford (48) 
CFA= confirmatory factor analysis; HDL= high-density lipoprotein cholesterol; HOMA= homeostatic model 
assessment for insulin resistance; Ins= fasting insulin; MAP= mean arterial pressure; MetS= metabolic 
syndrome; SBP= systolic blood pressure; TG= triglycerides; waist= waist circumference 
 
  There were 81 cases of type 2 diabetes during 11 years of follow-up in 790 middle-aged 
men. There were 126 acute myocardial infarctions during a median follow-up of 17.6 years, 
57 ischemic strokes during a median follow-up of 16.9 years, and 54 cases of coronary 
death, 88 cases of cardiovascular death and 215 cases of death in total during a median 
follow-up of 17.9 years in 1209 middle-aged men. The risk of type 2 diabetes increased 3.7-
fold with 1 SD increase in the cardiometabolic risk score (Table 20). The risk of myocardial 
infarction increased 1.4-fold and the risk of premature death due to coronary heart disease 
increased 1.8-fold with 1 SD increase in the cardiometabolic risk score. Also the risk of 
premature cardiovascular death increased 1.6-fold and the risk of premature overall death 
increased 1.4-fold with 1 SD increase in cardiometabolic risk score. The cardiometabolic risk 
score was not statistically significantly associated with the risk of ischemic stroke. The 
relations of the second-order confirmatory MetS factor variable and first-order 
confirmatory MetS factors with incident type 2 diabetes were slightly weaker (OR 3.0–3.3) 
than that of the cardiometabolic risk score (OR 3.7). The associations of the confirmatory 
MetS factors with myocardial infarction, ischemic stroke and premature coronary, 
cardiovascular and overall death were essentially equivalent to those of the cardiometabolic 
risk score. 
 
 Cardiometabolic 
risk score 
 
MetS 
factor 
(second-
order 
CFA)a 
MetS factor  
(first-order 
CFA) 
   bWaist–
HOMA–
TG/HDL–MAP 
Children (n=491)    
  MetS factor (first-order CFA)     
    bWaist–HOMA–TG/HDL–MAP 0.94 0.94  
    cWaist–Ins–TG/HDL–MAP 0.92 0.92 1.00 
    dWaist–Ins–TG–SBP 0.84 0.90 0.97 
  Cardiometabolic risk score  0.91 0.94 
Middle-aged men (n=900)    
  MetS factor (first-order CFA)     
    bWaist–HOMA–TG/HDL–MAP 0.93 0.99  
    cWaist–Ins–TG/HDL–MAP 0.91 0.99 1.00 
    dWaist–Ins–TG–SBP 0.90 0.98 1.00 
  Cardiometabolic risk score  0.92 0.93 
Older women (n=614)    
  MetS factor (first-order CFA)     
    bWaist–HOMA–TG/HDL–MAP 0.93 0.98  
    cWaist–Ins–TG/HDL–MAP 0.93 0.98 1.00 
    dWaist–Ins–TG–SBP 0.90 0.96 0.99 
  Cardiometabolic risk score  0.93 0.93 
Older men (n=555)    
  MetS factor (first-order CFA)     
    bWaist–HOMA–TG/HDL–MAP 0.93 0.95  
    cWaist–Ins–TG/HDL–MAP 0.93 0.96 1.00 
    dWaist–Ins–TG–SBP  0.90 0.94 0.99 
  Cardiometabolic risk score  0.92 0.93 
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5.3 Associations of I148M polymorphism in PNPLA3 gene with plasma 
ALT levels during 2-year follow-up in normal weight and overweight 
children (Study III)  
Altogether 58 (12%) of all 481 children examined at baseline and 71 (17%) of all children re-
examined after 2-year follow-up were overweight (Table 15). Of the 481 children examined 
at baseline, 283 (58.8%) were 148I homozygotes, 173 (36.0%) were I148M heterozygotes and 
25 (5.2%) were 148M homozygotes. Of the 419 children re-examined after 2-year follow-up, 
244 (58.2%) were 148I homozygotes, 153 (36.5%) were heterozygotes and 22 (5.3%) were 
148M homozygotes. There were no statistically significant differences in the genotype 
distributions of the rs738409 polymorphism between normal weight children (58.4%, 35.9%, 
5.7%) and overweight children (62.1%, 36.2%, 1.7%). 
   Body height, body weight, BMI-SDS, waist circumference, body fat percentage, insulin, 
LDL cholesterol, triglycerides and GGT were higher and HDL cholesterol was lower in 
overweight children than in normal weight children at baseline (Table 21). Increases in 
body weight, waist circumference and ALT during the 2-year follow-up were larger in 
overweight children than in normal weight children. BMI-SDS increased slightly during the 
2-year follow-up in normal weight children, while it decreased slightly in overweight 
children.  
   There were no statistically significant differences in cardiometabolic risk factors at 
baseline among the three PNPLA3 rs738409 genotypes (data not shown) or between the 
carriers and non-carriers of the 148M allele (Table 22). Systolic blood pressure increased in 
the PNPLA3 148M carriers, whereas it decreased in the PNPLA3 148M non-carriers.  
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Overweight children had higher plasma ALT levels at baseline (P=0.009) and a larger increase in 
plasma ALT levels during the 2-year follow-up (P<0.001) than normal weight children adjusted 
for age, sex, body height, carrying the PNPLA3 148M allele and change in BMI-SDS during the 
2-year follow-up. The carriers of the PNPLA3 148M allele had higher plasma ALT levels  at 
baseline than the non-carriers (18.3-19.2 U/l) only if they had overweight (23.2 U/l) but not if 
they had a normal body weight (18.2 U/l) at baseline (P=0.024 for interaction)  (Table 23, Figure 
5). The carriers of the PNPLA3 148M allele also had a larger increase in plasma ALT levels 
during the 2-year follow-up than the non-carriers (-0.6−0.3 U/l) only if they had overweight (6.4 
U/l) but not if they had a normal body weight (-0.3 U/l) at baseline (P=0.002 for interaction) 
(Table 23, Figure 5). Additional adjustments at baseline or for changes in these factors during 2-
year follow-up had little or no effect on these associations or interactions. There were no 
statistically significant differences in plasma GGT levels at baseline or after 2-year follow-up or 
changes in plasma GGT levels during 2-year follow-up between the PNPLA3 148M allele 
carriers and the non-carriers or between overweight children and normal weight children (data 
not shown). 
 
Table 23. The determinants of plasma alanine aminotransferase in all children 
 
     Baseline 2-year change 
Partial Eta  P-value      Partial Eta   P-value    
Squared  Squared    
Sex/female  0.002 0.280 0.000 0.951 
Age  0.001 0.424 0.005 0.146 
Body height  0.004 0.191 0.001            0.742 
Change in BMI-SDS    0.013            0.023 
during 2-year follow-up     
Overweight  0.020 0.002 0.050          <0.001 
PNPLA3 gene variant 
(I148I or I148M/M148M) 0.010 0.033 0.026 0.001 
Interaction between 0.011 0.024 0.023 0.002 
overweight and  
PNPLA3 gene variant   
Data are from general linear models including all these variables. BMI-SDS = body mass index standard 
deviation score, based on Finnish reference values (199).   
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Figure 5. Means (95% confidence intervals) of plasma alanine aminotransferase (ALT) according to the PNPLA3 
I148M polymorphism in normal weight and overweight or obese children. P-values for interaction between 
overweight/obesity and PNPLA3 gene variant (I148I or I148M/M148M): at baseline (P=0.024) (A) and for 2-
year change (P=0.002) (B). 
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6 Discussion 
6.1 Strengths and limitations 
6.1.1 Study populations and study designs 
The study population in Studies I-III consisted of children who participated in baseline 
examinations of the PANIC study when they were 6-8 years old and in 2-year follow-up 
examinations at the age of 8-10 years. Study II also included middle-aged men who participated 
in the baseline examinations of the KIHD study when they were 42-60 years old and older men 
and women who attended in the baseline examinations of the DR’s EXTRA study at the age of 
57-78 years. 
    The final study population of 512 children in the PANIC study represented about 70% of 736 
children 6-8 years of age who were originally invited in the study from the schools of the city of 
Kuopio. Altogether 86% of the 512 children participated in the 2-year follow-up study. Such a 
high participation rate in the 2-year follow-up study shows that the compliance of the 
participants was good. Furthermore, the participants of the baseline study did not differ in 
terms of age, height-SDS, weight-SDS or BMI-SDS from other children living in the city of 
Kuopio who had been examined by school nurses before the first grade. However, the non-
participant were not asked for their reasons for non-participating. Therefore, a possible 
selection bias must be taken into consideration. The participating families might have been 
more motivated and have healthier life style habits than non-participating families. The study 
population was rather homogenous in age, ethnicity and place of residence, mainly prepubertal, 
had not been exposed to smoking or alcohol consumption, excluding the possibility of the 
confounding effects of these factors. Moreover, the analyses were adjusted for several important 
confounding factors such as dietary factors, physical activity and sedentary behavior. Due to 
the cross-sectional nature of Study I and Study III considering other than middle-aged men, the 
directions of causality of observed associations cannot be determined. 
   The KIHD study provided a unique opportunity to investigate the associations of the 
clustering of cardiometabolic risk factors with the future risk of type 2 diabetes, myocardial 
infarction, ischemic stroke and premature CVD and total mortality in a population-based 
sample of 2682 men aged 42-60 years from the city of Kuopio who were at increased risk of 
coronary heart disease and who were followed-up for about 18 years. The 2682 participants of 
the KIHD study represented 83% of the 3235 men eligible for the study. The large representative 
population-based sample of middle-aged men makes it possible to generalize the findings to 
other male populations. However, the results cannot be extrapolated to other age groups or 
ethnic populations or to women.  
   The participants of the DR’s EXTRA study were a representative population-based sample of 
men and women 57-78 years of age from the city of Kuopio. About two thirds of the invited 
3000 individuals were initially willing to participate in the study. About three fourths of the 
individuals who were willing to attend finally participated in the baseline examinations. 
Because of the age range and the relatively long run-in period, it is understandable that some of 
those who had expressed their willingness to attend were not finally able to participate. The 
strengths of the study DR’s EXTRA study are the representative population-based sample, the 
inclusion of both men and women and the focus on older individuals.  
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6.1.2 Assessments 
Body composition and adiposity 
The prevalence of overweight and obesity was defined by the International Obesity Task Force 
(IOTF) criteria that use the age- and gender-specific BMI cutoffs (200). The IOTF criteria were 
used for the definition of overweight and obesity because it provides internationally 
comparable prevalence rates of overweight and obesity in children. The data for the IOTF 
criteria for overweight and obesity were obtained from cross-sectional surveys on growth in 
representative samples of children and adolescents aged 6-18 years from Brazil, Great Britain, 
Hong Kong, the Netherlands, and the United States. BMI is a widely used but crude measure of 
general body adiposity. Body weight and height are simple, inexpensive, safe and practical 
measurements (211), and it is easy to calculate BMI from body weight and height. However, a 
limitation of BMI is that it does not distinguish fat mass from muscle mass or bone mass. In 
elderly people, BMI may underestimate the level of body adiposity due to loss of skeletal 
muscle mass associated with aging. For an equivalent BMI, women have a much higher body 
fat percentage than men. In children BMI-SDS is more accurate compared to BMI because it 
takes into account the age and gender. We also computed the BMI-SDS values for children 
using previously published Finnish references (199). BMI also does not take body fat 
distribution into account. Despite these limitations, overweight and obesity in adults are 
generally classified according to the criteria of The WHO based on BMI (212). In a sample of 
over 4000 participants, a lower BMI in childhood was associated with a better cardiovascular 
health in adulthood (108). Moreover, data from the Bogalusa Heart Study and the 
Cardiovascular Risk in Young Finns Study showed that screening BMI offers an equally 
accurate alternative for MetS to identify youth at risk of developing adult MetS, subclinical 
atherosclerosis and type 2 diabetes (60). The cut-off points of the IOTF and the Centers for 
Disease Control identify children with a BMI higher than eighty-fifth percentile as “at risk of 
overweight” and children with a BMI higher than ninety-fifth percentile as “overweight” (200).  
    Body fat content among children in the PANIC study was also assessed using dual-energy x-
ray absorptiometry (DXA). The strength of DXA is that it is a more precise and valid method for 
assessing body fat percentage than other more commonly used measures of body composition 
(213). It also has a lower radiation risk than computed tomography. The PANIC study is one of 
the few population-based studies in children in which body fat content has been assessed using 
DXA.  
    Abdominal fat accumulation was estimated using waist circumference. Waist circumference 
is a cheap and easily available methods for assessing abdominal fat accumulation but it is 
subject to a relatively large measurement error due to inter-observed variability and differing 
anatomical sites of measurement (214). Waist circumference has been recognized as a simple 
and relatively good clinical measure of visceral fat accumulation (215). Elevated waist 
circumference is a useful preliminary screening tool for MetS and a key component in the 
definitions of MetS in adults. Variability in waist circumference between genders and ethnic 
groups means that a single universal cut-off point cannot be used. Further research is required 
to find a commonly agreed-upon set of gender-specific cut-off points for different ethnic groups 
(1). The prediction of health risks associated with overweight and obesity in youth has been 
found to be improved by assessing not only BMI but also waist circumference (216,217).  
   The amount of visceral and subcutaneous fat can be accurately visualized and quantified 
using MRI or computer tomography (218). However, these methods are too expensive to be 
used in large population-based studies. Another limitation of computed tomography is that it 
exposes to radiation. The determinants of visceral and subcutaneous fat and their associations 
with other risk factors have not been comprehensively studied in population samples of 
children and adolescents. Population-based studies among children and adolescents are needed 
to obtain information on lifestyle factors associated with decreased or increased risk of visceral 
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fat accumulation, to identify anthropometric measures which would help estimating the 
amount of visceral fat as well as  draw up norms specifying the amount of visceral fat among 
healthy children (121,218). 
Liver enzymes and the PNPLA3 gene polymorphism 
Elevated plasma levels of liver enzymes ALT and GGT have been associated with increased 
liver fat accumulation in children and adults (153,161). NAFLD is the most common reason for 
elevated plasma ALT levels (219), although normal ALT does not exclude steatosis (153). Other 
common reasons for elevated plasma levels of liver enzymes are excess alcohol consumption, 
viral hepatitis and hemochromatosis (153). A study in over 15 000 U.S. adults showed that the 
prevalence of elevated plasma levels of liver enzymes was 7.9% (219). Only 31% of the elevated 
levels were explained by excess alcohol consumption, viral hepatitis or hemochromatosis. In the 
remaining 69%, various features of MetS were strongly associated with an otherwise 
unexplained elevation of liver enzymes. Other studies have also shown a strong relationship 
between the features of MetS and the increased prevalence of NAFLD in adults and children 
(153,154). All children in the PANIC Study population had concentrations within the normal 
range for ALT (10-45 U/l in women and 10-70 U/l in men) and for GGT (10-45 U/l in women and 
10-80 U/l in men), as defined by the Nordic Reference Interval Project (NORIP) Study (220). 
There is no single standard cut-off point for abnormal high ALT or GGT levels in children, but 
the most commonly used limit for ALT is 40 U/l (21), which was exceeded by only five children.  
   In the present population study we were not able to measure liver fat content with MRI 
imaging or liver biopsy, which would have provided more detailed and accurate information 
about liver fat accumulation than plasma levels of ALT and GGT. However, in obese children 
increased serum ALT levels have been independently associated with the increased prevalence 
of NAFLD and excess hepatic fat content, as assessed by MRI, although ALT alone was not 
accurate enough to be employed as a marker of NAFLD (221,222). According to the 
questionnaire administered by the parents none of the children in the PANIC cohort had type 1 
diabetes, celiac disease, hepatitis, mononucleosis, toxic diseases or other rare hepatological or 
pancreatic diseases that could have increased liver enzyme levels. Also some medicines could 
increase liver enzyme levels. Altogether nine children used such medication regularly, and two 
of them had rheumatoid arthritis and one inflammatory bowel disease. However, the results 
remained similar even after exclusion of these children. We were unable to evaluate the effect of 
irregular use of pain or allergy medicines. The consumption of alcohol and energy drinks could 
also increase liver enzyme levels, but even surreptitious use is unlikely at the age of 6-8 years, 
and according to the 4-day food records administered by the parents children did not consume 
them yet at this age. In addition, because plasma levels of liver enzymes fluctuate from day to 
day, one measurement of ALT and GGT may somewhat underestimate the true associations.  
   The prevalence of NAFLD among children and adolescents is unknown, and there are no 
established criteria for abnormal serum ALT levels due to lack of population-based studies in 
these age groups (161). The few previous population-based studies related to pediatric or 
adolescence NAFLD have included only limited and relatively insensitive measurements of 
liver fat accumulation such as serum ALT levels (223,224) or ultrasound examination (225). 
There are no population-based studies on hepatic fat accumulation assessed by MRI or liver 
biopsy, the relation of hepatic fat accumulation to other cardiometabolic risk factors or the 
predictors of hepatic fat accumulation among children or adolescents. Such studies are needed 
to find proper cut-off points for serum or plasma ALT levels to be used in clinical practice and 
research.  However, such studies would be expensive and taking invasive liver biopsies for 
research purposes would also be unethical. 
    Genotyping the rs738409 polymorphism in the PNPLA3 gene was performed with standard 
methodology. The genotype distribution of the rs738409 polymorphism was within Hardy-
Weinberg equilibrium. A weakness of the PNPLA3 study is the relatively small study sample 
for a genetic study. Due to small sample size we also had to compare plasma ALT levels in the 
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148M allele carriers and the non-carriers. However, not only the M148M genotype but also the 
I148M genotype has been associated with increased levels of plasma ALT although the ALT 
levels have been higher among the homozygotes (26,226,227). 
Metabolic syndrome and cardiometabolic risk score 
The definition of MetS is particularly controversial among children and adolescents, because 
there are no clear thresholds above which the cardiometabolic risk factors start to worsen 
(2,11,12). Therefore, many of the more recent studies among children have used continuous 
variables for the components of MetS and have calculated a continuous cardiometabolic risk 
score instead of using a definition based on dichotomous variables (13-15). Using a continuous 
cardiometabolic risk score variable for the key features of MetS instead of a dichotomous 
variable for the syndrome is reasonable because there is no evidence for a clear threshold above 
which cardiometabolic risk increases (51). Another reason for using a continuous variable 
instead of a dichotomous variable is that continuous variables better describe the true 
pathophysiological processes and increase statistical power in analyses. In the PANIC study a 
continuous cardiometabolic risk score variable was calculated using continuous z-score 
variables for the components of MetS, as employed previously (61)  The cardiometabolic risk 
score was calculated as waist circumference + insulin + glucose - HDL cholesterol + triglycerides 
+ the mean of systolic and diastolic blood pressure a higher score indicating a less favorable 
cardiometabolic risk profile. The cardiometabolic risk score was validated in children, in 
middle-aged men as well as in older men and women. However, a weakness of the 
cardiometabolic risk score is that it can currently be used only in research, because further 
investigation is needed to define cut-off points for risk estimation in clinical practice. Also, the 
results dealing with clinical outcomes can be generalized only to men because of the study 
sample used. Fasting insulin has not been included in most definitions of MetS in which 
dichotomous variables have been used, because methods for the measurement of fasting insulin 
are not commonly used in clinical practice and because there is wide variation in fasting insulin 
values among assays available. However, systematic differences in insulin assays, other 
biochemical analyses or measurement of blood pressure between children, middle-aged men 
and older men and women are unlikely to have major effects on the conclusions of this thesis.  
  
Factor analysis 
Factor analysis has also been used to describe the pathophysiological processes related to MetS 
(16,17). Exploratory factor analysis has traditionally been used to explore the possible 
underlying factor structure of a set of observed variables without imposing a preconceived 
structure on the outcome. In previous literature the number of factors identified has ranged 
from 1 to 5 (41). Studies with higher number of starting components have produced larger 
number of factors. Also the specific variables included and rotation method applied in the 
analysis have influenced the results. The results of individual factor analyses should therefore 
be considered suggestive of underlying biological relationships. The actual underlying 
mechanisms, which are only partly understood, are certainly more complex. In Study I, 
exploratory factor analysis with promax rotation was used. The promax rotation allows factors 
to be correlated, as opposed to the more commonly used varimax rotation, which generates 
uncorrelated factors. Uncorrelated factors may simplify interpretation of the factors, but may 
not be biologically relevant (46).  CFA, on the other hand, can be used to test the hypothesis that 
the MetS can be represented as a single entity (47). We carried out second-order CFAs in which 
the MetS was represented by a second-order latent variable underlying four latent variables 
characterized by abdominal obesity, insulin resistance, dyslipidemia and raised blood pressure 
in different age groups. Previous studies using CFA model to represent MetS (17,48,50) have 
performed first order factor analyses with slight differences in the variables used. Shen et al. 
(2003) used a hierarchical CFA model with 10 measured variables in which the latent obesity, 
insulin resistance, lipid and blood pressure variables were allowed to covary (49). The analysis 
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indicated that all four latent variables loaded on each other, and the model fit the data well in 
the entire cohort and in various age groups. The second-order factor analysis in Study II is 
conceptually similar to this hierarchical analysis, differing mainly in that the MetS was 
described as a second-order latent factor instead of implicitly through the covariance of the 
latent first-order variables. 
6.2 Interpretation of findings and comparison with previous findings 
6.2.1 Associations of cardiometabolic risk factors with high-normal plasma levels of liver 
enzymes (Study I) 
Study I showed that the features of MetS cluster among prepubertal children. Factor analyses 
revealed a MetS factor characterized by a larger waist circumference, higher levels of fasting 
insulin, fasting glucose, triglycerides, hsCRP, and GGT and lower levels of HDL cholesterol. 
Children in the highest gender-specific third of cardiometabolic risk score, body fat percentage, 
waist circumference and insulin had a 2-3–times higher risk of being in the highest fifth of ALT 
and GGT adjusting for age and body height. Moreover, children in the highest third of glucose 
and hsCRP had a 2.5-fold risk of being in the highest fifth of GGT. While the associations of 
body fat percentage and waist circumference with ALT and GGT generally remained after 
further adjustment for other features of MetS and confounding factors, the relationships of 
other features of MetS generally were no longer associated with ALT and GGT after additional 
adjustment for fat percentage and waist circumference. These findings suggest that the features 
of MetS and especially total and abdominal adiposity increase the likelihood of having high-
normal levels of ALT and GGT. The few previous studies on the associations of MetS and its 
components with high-normal levels of liver enzymes in children have found associations of the 
features of MetS with higher levels of ALT, and most of these studies have been carried out 
among obese children (166,167,228). The Bogalusa Heart Study showed that MetS and all of its 
major components were associated with higher serum levels of ALT within the normal range 
among apparently healthy preadolescents and adolescents (167). Other smaller studies among 
overweight or obese children have provided further evidence for the associations of MetS and 
its components with higher serum levels of liver enzymes within the reference range (166,228). 
   Previous studies in adults suggest that even high-normal levels of liver enzymes are 
associated with an increased risk of developing type 2 diabetes and CVD (168,229) and that 
even small changes in liver enzymes could indicate a potential dysmetabolic state (230). 
Together with these studies, the present findings suggest that GGT and ALT could be used as 
continuous biomarkers of metabolic risk not only in adults but also in prepubertal children and 
that the adult cut-off points may be too high for children. In the present study, GGT generally 
correlated more strongly with the features of MetS than ALT. Hence, GGT might be a more 
specific indicator of metabolic dysfunction, particularly abnormal insulin and glucose 
metabolism and systemic inflammation, as assessed by hsCRP, than ALT in children. Moreover, 
the association between fasting glucose and GGT remained even after controlling for body 
adiposity as reported previously in mainly overweight and obese Pima Indian children (166).   
   The association between MetS and elevated liver enzymes might be related to increased 
central adiposity and insulin resistance (168,231,232). Increased metabolic activity and excess fat 
accumulation in the liver appear to increase gluconeogenesis, lipogenesis and triglyceride 
secretion (19,233). Other mechanisms by which fat accumulation in the liver may worsen insulin 
resistance and dyslipidemia include exacerbation of inflammation and oxidative stress (19). 
Also some studies in adults suggest that elevated serum levels of ALT and GGT are 
independent markers of systemic low-grade inflammation and oxidative stress, irrespective of 
their association with MetS, and have been related to higher CRP concentrations (234,235). Our 
results suggest that overweight and related cardiometabolic risk factors elevate liver enzymes 
in otherwise healthy children. Therefore, it is crucial to pay attention to the presence of 
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cardiometabolic risk factors in children with elevated or high-normal values of liver enzymes. 
The currently used cut-off points for elevated ALT and GGT in children might be too high.  
6.2.2 Validation of cardiometabolic risk score by confirmatory factor analysis in children and 
adults and prediction of cardiometabolic outcomes in adults (Study II) 
 There are three main findings in Study II. First, the MetS factors derived from the first- and 
second-order CFAs were strongly associated with a composite cardiometabolic risk score in 
children, middle-aged men, and older women and men. This suggests that the continuous 
cardiometabolic risk score variable can be used in different age groups to represent the 
clustering of the components of MetS. Second, MetS could be reasonably well described as a 
single entity in boys and girls, middle-aged men, and older men and women in the first- and 
second-order CFAs. However, the results suggest that waist circumference is a less prominent 
feature of MetS in children than in adults and that blood pressure is a more important feature of 
MetS in middle-aged men than in children or older adults. Third, the MetS factors derived from 
the first- and second-order CFAs and the cardiometabolic risk score similarly predicted incident 
type 2 diabetes, myocardial infarction, ischemic stroke, and mortality from coronary heart 
disease, CVD and any cause in middle-aged men. These findings indicate that the 
cardiometabolic risk score could be a useful tool in research for the evaluation of 
cardiometabolic risk in children and adults. 
   A couple of previous studies have also used a cardiometabolic risk score in the assessment of 
risk for clinical outcomes. A recent study in Indian children demonstrated that a continuous 
cardiometabolic risk score had a stronger direct association with subclinical atherosclerosis than 
individual components of MetS (15). A higher cardiometabolic risk score has also been 
associated with a markedly increased risk of developing type 2 diabetes and CVD in adults (18). 
Study II provides further evidence for the usefulness of the cardiometabolic risk score to 
represent the clustering of cardiometabolic risk factors in different age groups and for the 
ability of the cardiometabolic risk score to predict incident type 2 diabetes, CVD and premature 
mortality in adults.  
   Recent studies using CFA have found a single factor underlying MetS in children (17), 
adolescents (48) and adults (50). These studies have used parsimonious models with four 
variables to represent the features of the MetS. These models also fit the data in our four 
cohorts, although for the models using the triglycerides to HDL cholesterol ratio and MAP 
(17,50) instead of triglycerides and systolic blood pressure (48) the RMSEA was unacceptably 
high in middle-aged men and older women. 
   The pathophysiology of the MetS is not well understood, but multiple genetic and lifestyle 
factors certainly interact in its development (12,236). Even though the MetS does not have a 
single cause, findings from our study and other studies suggest that the MetS can be described 
as a single entity in cohorts ranging from children to older adults, and in men and women 
(17,48-50,237). However, this does not confirm the significance of MetS as a diagnostic category, 
which is much disputed (37). 
   In a recent study among women, a number of combinations of risk factors were entered in the 
CFA and the factors identified predicted type 2 diabetes and CVD (238). However, there is little 
evidence on whether the factorial structure of MetS works in the same way in different stages of 
life. In a recent study among Estonian and Swedish young people a single factor describing 
MetS was stable across puberty (237). We identified a similar MetS factor in children, middle-
aged men and older men and women by CFA, although waist circumference was a less 
prominent determinant in children than in adults, and blood pressure loaded more heavily in 
middle-aged men than in children or older adults.  
   The accumulation of fat, particularly in the abdominal or visceral region, is considered a key 
feature of MetS (29). The present CFA suggests that clustering of cardiometabolic risk factors 
seems to exist among children in a corresponding manner as among middle-aged and older 
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adults, although waist circumference seemed to be a more crucial factor in adults than in 
children. This may partly be due to the lesser number of overweight or obese individuals and a 
shorter exposure to the adverse cardiometabolic consequences of overweight among children 
than among adults. Another reason for our finding may be that fat is more evenly distributed in 
the body of children (239,240). Abdominal adiposity, assessed by waist circumference in our 
study, may therefore provide less information beyond overall adiposity in predicting 
cardiometabolic risk in children than in adults. Also, the variation of body adiposity is 
relatively small in our study population of children. Central adiposity was less prominent in 
our study population of children than in previous studies in children (17,237). Only a few 
children were obese (3.9%) and also the prevalence of overweight, defined by the IOTF criteria 
(200), was relatively low (8.4%), which may have reduced factor loading for waist 
circumference. Insulin resistance is also an important feature of MetS (2,12,29). Excess fat 
accumulation in the liver has been observed to increase hepatic gluconeogenesis, lipogenesis 
and triglyceride secretion (19,233). Consistent with these findings, we observed that fasting 
serum insulin and plasma triglycerides were key components of MetS in all age groups and in 
both genders.  
   As in other studies (17,48-50,237) elevated blood pressure was a less prominent feature of the 
MetS than other core features. Blood pressure loaded more strongly on the MetS factor in 
middle-aged men than in the other cohorts. In older men and women, the reason for this is 
partly, but not entirely, that antihypertensive medication confounds the association between 
blood pressure and cardiometabolic risk. Blood pressure medication was associated with more 
pronounced features of the MetS, but antihypertensive medication lowers blood pressure, thus 
attenuating the relationship of blood pressure to the MetS. The use of blood pressure 
medication was especially prevalent in older men and women (almost 40%). In the first-order 
CFAs, the loading of blood pressure was higher (0.24 – 0.31 in women and 0.18 – 0.26 in men) in 
older men and women not using antihypertensive medications than in all older men and 
women. This obviously does not explain the lower loading of blood pressure in children. It may 
be that blood pressure is more adversely affected by risk factors after a longer exposure. Blood 
pressure also generally loaded more weakly on the MetS factor in the first-order CFA model 
using systolic blood pressure instead of MAP. This is probably because systolic blood pressure 
was slightly less strongly associated with features of the MetS than diastolic blood pressure or 
MAP. The substitution of diastolic blood pressure or MAP for systolic blood pressure gave 
higher loadings. 
6.2.3 Associations of I148M variant in PNPLA3 gene with plasma ALT levels during 2-year 
follow-up in normal weight and overweight children (Study III) 
Study III showed that plasma ALT levels were higher at baseline and after the 2-year follow-up 
and that plasma ALT levels increased more during the 2-year follow-up in the PNPLA3 148M 
allele carriers than in the non-carriers if they were overweight but not if they had a normal body 
weight. These differences were independent of a number of possible confounding factors. 
   Other studies in Caucasian populations have included only obese children and have shown 
that the PNPLA3 148M allele carriers have higher plasma ALT levels than the non-carriers 
(177,178). However, studies in Hispanic children, who have a higher proportion of the 148M 
allele carriers than most other populations, have reported higher plasma ALT levels in the 148M 
allele carriers than in the non-carriers not only among overweight or obese children but also 
among normal weight children (28,176). The results of Study III are in line with those of 
previous studies which suggest that the association of the I148M allele with hepatic fat 
accumulation or higher plasma ALT levels is evident in the presence of adiposity-related risk 
factors, such as severe obesity (25) and visceral adiposity (177). There were no associations of 
the PNPLA3 rs738409 polymorphism with plasma GGT levels, measures of body fat content or 
markers of glucose and lipid metabolism, including BMI-SDS, body fat percentage, waist 
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circumference, insulin, glucose, triglycerides, LDL cholesterol and HDL cholesterol. There are 
no previous reports on the associations of the PNPLA3 rs738409 polymorphism with plasma 
levels of GGT in children. Some previous studies in adults have not shown an association 
between PNPLA3 rs738409 polymorphism and GGT (174), but one recent study found such an 
association (241). Other previous studies among children have not reported an association of 
the PNPLA3 I148M polymorphism with measures of glucose metabolism, either 
(28,174,176,177). The results of some studies in children suggest that the 148M allele carriers 
have lower plasma levels of HDL cholesterol and a lower BMI than the non-carriers (28,176), 
but some other studies in children have not confirmed these findings (174,177).   
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7 Conclusions 
1. MetS can be represented as a single entity in children, middle-aged men, and older 
women and men by confirmatory factor analysis. The cardiometabolic risk score 
consisting of common features of MetS can be used to assess the clustering of 
cardiometabolic risk factors not only in children, but also in different stages of 
adulthood. Moreover, the cardiometabolic risk score predicts incident type 2 diabetes, 
myocardial infarction, and premature CVD and overall mortality similarly to MetS 
factors derived from first- and second-order CFAs. Thus the cardiometabolic risk score is 
a useful tool for research evaluating cardiometabolic risk in different age groups.  
 
2. The clustering of cardiometabolic risk factors, particularly excess body fat content, was 
associated with high-normal plasma levels of ALT and particularly GGT in children. 
Liver fat accumulation may play an important role in the pathogenesis of MetS and its 
consequences beginning already in childhood.  
 
3. Healthy children who carry the 148M allele of the PNPLA3 rs738409 polymorphism had 
high-normal plasma levels of ALT if they were overweight but not if they had a normal 
body weight. On the other hand, overweight children had higher plasma ALT levels than 
normal weight children even without the risk allele. These findings suggest that the early 
prevention of overweight particularly among children carrying the PNPLA3 148M allele 
may help avoid liver fat accumulation and the development of NAFLD. 
 
 
7.1 Clinical implications 
The findings of the present study suggest that plasma GGT and ALT could be used as 
continuous biomarkers of cardiometabolic risk not only in adults but also in prepubertal 
children and that the adult cut-off points may be too high for children. When evaluating the risk 
of type 2 diabetes and CVD in clinical practice, attention should be paid to the levels of all major 
cardiometabolic risk factors. The findings of this study also emphasize the early prevention of 
overweight among children and particularly among those carrying the PNPLA3 148M allele to 
avoid liver fat accumulation and the development of NAFLD.  
7.2 Future research prospectives 
Based on the present study, future research is needed to find clinically useful cut-off points for 
plasma ALT and GGT as well as other cardiometabolic risk factors among children. Studies on 
the associations of cardiometabolic risk factors with liver fat accumulation assessed using MRI 
and the effects of lifestyle interventions on hepatic fat accumulation in population samples of 
healthy children would be scientifically interesting and important. Plasma levels of liver 
enzymes should be measured more actively among obese and even overweight children. 
Moreover, the role of PNPLA3 gene variant in the accumulation of liver fat as assessed by MRI 
should be studied in normal weight and overweight children. Furthermore, to use the 
cardiometabolic risk score in clinical practice, further research is needed to define the 
population-specific cut-off points for the identification of high-risk individuals. The early 
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detection of children at increased risk of MetS and lifestyle interventions targeted to these 
children are important to prevent or at least delay the onset of MetS and related disorders. 
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